Annual Cancer Symposium - 2010 Scientific Program - Posters
Go To: Wednesday's Sessions | Thursday's Sessions | Friday's Sessions | Saturday's Sessions | Sunday's Sessions | All Posters
Basic Science
P1 Modulation of Immune Checkpoint B7-H1/PD-1 Interaction Improves Immunotherapy in the Treatment of Hepatic Colorectal Metastasis
B.H. Edil,* K. Olino, X. Pan, S. Wada, W. Weber,
D.M. Pardoll, R.D. Schulick, K. Yoshimura. Surgery, Johns
Hopkins, Baltimore, MD.
P2 Withdrawn
P3 The Relationship Between Notch1 and Akt-mTOR Signaling in Neuroendocrine Tumors
S.C. Pitt,* R.J. Davis, R. Jaskula-Stzul, M. Kunnimalaiyaan,
H. Chen. University of Wisconsin, Madison, WI.
P4 Surgery Enhances Bone Marrow Derived Cell Mobilization and Increases Metastasis in a Mouse Melanoma Model
S. Lavotshkin,1* T.M. Theilen,2 S.R. Granitto,1
D. Rutigliano,2 L. Rotman,1 M.P. LaQuaglia,2 R.N. Kaplan,1
D. Lyden.1 1. Weill Cornell Medical College, New York, NY;
2. Memorial Sloan-Kettering Cancer Center, New York, NY.
P5 CD4 Lymphocytes Transduced with an MHC Class I Receptor Can Mediate Tumor Regression Following Adoptive Cell Transfer
T.L. Frankel,* W. Burns, S.A. Rosenberg, R.A. Morgan.
National Cancer Institute, Bethesda, MD.
P6 Pancreatic Cancer-Associated Fibroblasts and ErbB3-mediated Tumorigenesis
J.S. Liles,1* A. Frolov,1 P. Kulesza,2 J.D. Christein,1
M.J. Heslin,1 J.P. Arnoletti.1 1. Department of Surgery,
University of Alabama at Birmingham, Birmingham, AL;
2. Northwestern University - Department of Pathology,
Chicago, IL.
P7 High Throughput Oncogene Profiling in Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas
N. Lubezky,1* Y. Cohen,3 M. BenHaim,1 R. Nackache,1
S. Marmor,2 G. Rechavy,3 J.M. Klausner.1 1. Department of Surgery B, TelAviv Sourasky Medical Center, TelAviv, Israel; 2. Institute of Pathology, TelAviv Sourasky Medical Center, TelAviv, Israel; 3. Cancer Research Center, Sheba Medical Center, TelHashomer, Israel.
P8 Improved Survival with Pre-resectional Radiofrequency Ablation is Associated with Enhanced CD8 T Lymphocyte Trafficking to Tumor-draining Lymph Nodes and Tumor Sites
F. Ito,1* J.B. Muhitch,2 T. Vardam,2 M.M. Appenheimer,2
D.T. Fisher,2 W.C. Wang,2 S.O. Gollnick,2 S.S. Evans.2
1. Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY; 2. Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY.
P9 Vaccinia Virus Mutant with Enhanced Extracellular Virion Production is a More Effective Oncolytic Agent in the Presence of Humoral Immunity
P. Thirunavukarasu,* M. Sathaiah, M. O'Malley, M. Gorry,
J. Li, F. Austin, S. Guo, D. Bartlett. University of Pittsburgh Medical Center, Pittsburgh, PA.
P10 Tyrosine Kinase Inhibitor Lapatinib Inhibits Cell Growth and Induces Apoptosis in Pancreatic Carcinoma Cells, and Exerts Synergistic Effects With Conventional Chemotherapy Agents
S. Singla,* J.A. Pippin, J.A. Drebin. Surgery, University of Pennsylvania, Philadelphia, PA.
P11 Ischemia Modulates Tumor Growth and Spread in a Murine Lung Cancer Model: The Role of Host Immunity
E.G. Sheu,* K. Wakatsuki, S.M. Oakes, F.D. Moore, Jr..
Brigham and Women's Hospital, Boston, MA.
P12 The Role of Epithelial to Mesenchymal Transition in Colorectal Cancer Therapeutic Resistance
E.R. Camp,* S.G. Vaena, V.J. Findlay, J.P. Stokes, E.G. Hill,
D.N. Lewin, N.F. Esnaola, D.J. Cole, D.P. Turner,
D.K. Watson. Surgery, Medical University of South Carolina, Charleston, SC.
P13 Soluble Factors in the Chemoresistant Colorectal Cancer Secretome
D. Bose,1* F. Tozzi,1 L. Zimmerman,2 M. Herynk,1 F. Fan,1
S. Samuel,1 A. Parikh,2 R. Slebbos,2 E. Petricoin,3
D. Liebler,2 L.M. Ellis.1 1. MD Anderson Cancer Center, Houston, TX; 2. Vanderbilt University, Nashville, TN;
3. George Mason University, Fairfax, VA.
P14 Identifying Tumor-Associated Antigens Recognized by Therapeutic B Cells Used in Adoptive Immunotherapy
J.P. Namm,* Q. Li, J. He, D.M. Lubman, A.E. Chang.
Surgery, University of Michigan, Ann Arbor, MI.
P15 Inhibition of IL-4 Leads to Resolution of Lymphedema and Fibrosis in a Mouse Model
T. Avraham,* S. Daluvoy, E. Kueberuwa, J. Zampell,
B.J. Mehrara. Surgery, Memorial SloanKettering Cancer Center, New York, NY.
P16 Human Melanomas are Sensitive to Inhibition of Polyamine Synthesis
E.C. Hsueh,* Y. Zhang, G. Peng. Saint Louis University, St. Louis, MO.
P17 Fas Ligand Expression Increases Safety and Tumor Selectivity of Vaccinia Virus
P. Thirunavukarasu,* M. Sathaiah, M. O'Malley,
M. Kavanagh, F. Austin, H. Zeh III, S. Guo, D. Bartlett.
University of Pittsburgh Medical Center, Pittsburgh, PA.
P18 A New Oncolytic Poxvirus Expresses Tetracycline-Inducible GM-CSF for Cancer Therapy
F. Austin,* M. Gorry, M. O'Malley, M. Sathaiah,
P. Thirunavukarasu, J. Li, Z.S. Guo, D.L. Bartlett. Surgical Oncology, University of Pittsburgh, Pittsburgh, PA.
P19 Cytokine Levels Correlate With Immune Cell Infiltration After Anti-VEGF Therapy In Preclinical Mouse Models of Breast Cancer
C.L. Roland,* K.D. Lynn, J.E. Toombs, S.P. Dineen,
R.E. Schwarz, D.G. Udugamasooriya, R.A. Brekken. UT Southwestern Medical Center, Dallas, TX.
P20 Withdrawn
P21 Withdrawn
P22 Gene Expression Analysis of a Notch1 Overexpression Model of Medullary Thyroid Carcinoma
M. Roy,* P. Geiger, G. Kennedy, M. Kunnimalaiyaan,
H. Chen. Surgery, UW, Madison, WI.
* designated presenter
P23 Expression Patterns of Notch1 and Its Ligands in Well-Differentiated Thyroid Cancers
X. Yu,* A. Lund, M. Kunnimalaiyaan, H. Chen. Endocrine Surgery Research Laboratories, Department of Surgery, and the University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI.
P24 STAT2 Activation is Required for HPP1-Mediated Tumor Suppression
J.M. Hernandez,* A. Elahi, D. Shibata. GI Oncology, Moffitt Cancer Center and Research Institute, Tampa, FL.
P25 Modified Vaccinia Virus Improves Survival in a Murine Peritoneal Carcinamatosis Model
A.A. Mavanur,* D.L. Bartlett. Division of Surgical Oncology, UPMC, Pittsburgh, PA.
P26 Effects of Microwave (MW) Ablation on Blood Vessels
A.B. Ross,* P. Manley, J. Coe, C. Ladtkow. Interventional Oncology, Covidien, Boulder, CO.
Disclosure: Employee: Covidien
P27 Sphingosine Kinase 1: A New Target Against Breast Cancer
M. Nagahashi,* S. Ramachandran, O. Rashid, S. Milstien,
S. Spiegel, K. Takabe. Virginia Commonwealth University, Richmond, VA.
P28 Comparative Proteomic Analysis of 5-Fluorouracil and Oxaliplatin Resistant Colorectal Cancer Cells
D. Bose,1* F. Fan,1 L. Zimmerman,2 R. Slebbos,2
A. Parikh,2 D. Liebler,2 L.M. Ellis.1 1. MD Anderson Cancer Center, Houston, TX; 2. Vanderbilt University, Nashville, TN.
P29 Withdrawn
P30 HIF-1? Regulates VEGF-C Expression and Is Required for Lymphangiogenesis
J. Zampell,* S. Daluvoy, T. Avraham, E. Kueberuwa,
A. Yan, B. Mehrara. Surgery, Memorial SloanKettering, New York, NY.
Breast Cancer
P31 Molecular Characterization of Breast Cancer Progression: Early Lesions Are Not Genetically Advanced
R. Ellsworth,1* J.D. Weyandt,2 J.L. FantaconeCampbell,3
B. Deyarmin,2 D.L. Ellsworth,2 J.A. Hooke,3 C.D. Shriver.3
1. Henry M. Jackson Foundation for the Advancement of Military Medicine, Windber, PA; 2. Windber Research Institute, Windber, PA; 3. Walter Reed Army Medical Center, Washington, DC.
P32 Basal Phenotype Predicts Worse Survival in HER2Positive Breast Cancer Patients
S.P. Bagaria,1* P.S. Ray,1 J.M. Shamonki,2 A.P. Chung,1
X. Cui,3 A.E. Giuliano.1 1. Department of Surgical Oncology, John Wayne Cancer Institute, Santa Monica, CA; 2. St. John's Health Center Department of Pathology, Santa Monica, CA; 3. John Wayne Cancer Institute Department of Molecular Oncology, Santa Monica, CA.
P33 Does Florid Lobular Carcinoma In Situ Behave Like a Precursor Lesion of Invasive Lobular Carcinoma?
S.P. Bagaria,1* J.M. Shamonki,2 P.S. Ray,1 A.E. Giuliano.1
1. Department of Surgical Oncology, John Wayne Cancer Institute, Santa Monica, CA; 2. St. John's Health Center, Department of Pathology, Santa Monica, CA.
P34 Disparities in Reconstruction Rates after Mastectomy
A. Holt,* L. Duan, K. Henderson, L. Bernstein, J. Ta,
J. Ellenhorn, L. Kruper. City Of Hope, Duarte, CA.
P35 The Role of Axillary Staging in Women Diagnosed with Microinvasive DCIS (DCISM)
Pimiento,* M.C. Lee, N.N. Esposito, J.V. Kiluk,
Khakpour, W.B. Carter, G. Han, C. Laronga. H. Lee Moffitt Cancer Center, Tampa, FL.
P36 Post-excision Mammography (PEM) Has a Limited Role in Assessing for Residual Disease (RD) After BCS
M. Morrogh,* R. Sakr, E. Kueberuwa, A. Park, T.A. King.
MSKCC, New York, NY.
P37 Withdrawn
P38 Are Mastectomy Rates Really Increasing in the United States?
E.B. Habermann,* A. Abbott, H.M. Parsons, B.A. Virnig,
W.B. AlRefaie, T.M. Tuttle. Surgery, University of Minnesota, Minneapolis, MN.
P39 Ipsilateral Breast Cancer Recurrence after Transverse
Rectus Abdominal Muscle (TRAM) Reconstruction
S.G. Patterson,1* G.W. Carlson,2 T.M. Styblo,2 A. Losken,2
M. Torres,3 W.C. Wood,2 M. Rizzo.2 1. Avon Breast Cancer Center at Grady, Atlanta, GA; 2. Department of Surgery Emory University School of Medicine, Atlanta, GA;
3. Department of Radiation Oncology, Atlanta, GA.
P40 Radiologic Presentation of Breast Papillary Lesions
M. Lowe,1* J. Park,2 L. Pan,3 S.G. Gabram,1 M. Mosunjac,2
M. Rizzo.1 1. Department of Surgery, Emory University School of Medicine, Atlanta, GA; 2. Pathology and Laboratory Medicine, Atlanta, GA; 3. Biostatistics, Atlanta, GA.
P41 Intraoperative Imprint Cytology of Sentinel Nodes in Patients with Breast Cancer -Costly or Cost Effective?
J.P. Kaminski,* D. Case, M. HowardMcNatt,
K.R. Geisinger, E.A. Levine. Surgical Oncology, Wake Forest University School of Medicine, WinstonSalem, NC.
P42 Molecular Breast Imaging in the Preoperative Surgical Workup of Women with Biopsy Proven Breast Cancer
J.C. Boughey,1* M.K. O'Connor,2 C.B. Hruska,2 L. Neal,3
J.W. Jakub,1 A.C. Degnim,1 R.W. Maxwell,4 C.L. Tortorelli,4
D.J. Rhodes.3 1. Surgery, Mayo Clinic, Rochester, MN;
1 Nuclear Medicine Mayo Clinic, Rochester, MN;
2 Internal Medicine Mayo Clinic, Rochester, MN;
3 Breast Imaging Mayo Clinic, Rochester, MN.
P43 Usefulness of Pre-Operative Axillary Ultrasound in Early Stage Breast Cancer Patients
J. CoolsLartigue,1* N. Trabulsi,1 A. Sinclair,2 A. Meguerditchian,1 B. Mesurolle,1 R. Fuhrer,2 S.H. Meterissian.1 1. McGill University Health Center, Montreal, QC, Canada; 2. Department of Epidemiology, McGill University, Montreal, QC, Canada.
P44 Novel STAT3 Inhibitor in the Treatment of Breast Cancer
M. Senthil,* Q. Xing, J. Yin, R. Buettner, D. Horne,
R. Jove, J. Yim. General oncologic surgery, City of Hope, Duarte, CA.
P45 Cumulative Findings from the E75 Peptide Vaccine
Adjuvant Trials in Breast Cancer
G.T. Clifton,1* K. Clive,1 J.P. Holmes,2 R. Patil,3
L.C. Benavides,1 J.D. Gates,1 E.A. Mittendorf,4
A. Stojadinovic,5 S. Ponniah,6 G.E. Peoples.1 1. Brooke Army Medical Center, Ft. Sam Houston, TX; 2. Naval Medical Center San Diego, San Diego, CA; 3. Windber Medical Center, Windber, PA; 4. U.T.MD Anderson Cancer Center, Houston, TX; 5. Walter Reed Army Medical Center, Washington, DC; 6. Cancer Vaccine Development Program, USUHS, Bethesda, MD.
P46 Axillary Lymph Node Response after Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
I. Qureshi,* L. Samiian. University of Florida at Jacksonville, Jacksonville, FL.
P47 Breast MRI Tumor Size as a Predictor of Response to Neoadjuvant Chemotherapy
M.M. Williams,* J.M. Eatrides, J. Kim, J.V. Kiluk, M.C. Lee,
C. Laronga, N. Khakpour. Moffitt Cancer Center, Tampa, FL.
P48 Response to Neoadjuvant Chemotherapy is Not Associated with Improved Results for Sentinel Lymph Node Biopsy in Patients with Inflammatory Breast Cancer
S. Bloom,* H.S. Cody. Memorial SloanKettering Cancer Center, New York, NY.
P49 Are Increased Mastectomy Rates Based on Pretreatment MRI Findings Justified?
K. Clive,* J.A. Tyler, M.F. Barchie, J.B. Sutcliffe,
A.D. Kirkpatrick, K.P. Banks, L.M. Bell, J.S. Saenger,
G.E. Peoples. General Surgery, Brooke Army Medical Center, San Antonio, TX.
P50 Intraoperative Injection of Low Dose 99mTc Sulfur Colloid for Sentinel Node Biopsy: An Aid to Resource Conservation
E. Tran,1* B.J. Grube,1 D. Cheng,2 B. Killelea,1 M. Rishi,1
D. Lannin.1 1. Yale New Haven Breast Center, New Haven, CT; 2. Yale University, Department of Radiology, New Haven, CT.
P51 The Effect of Incision Choice on Outcomes of Nipple-Sparing Mastectomy Reconstruction
J.Y. Kim,* V. Rawlani, S. Khan, N. Hansen, J. Fiuk, S.A. Johnson, E. Hirsch, N.A. Fine. Department of Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL.
Disclosure: Grant/Research Support: Musculoskeletal Transplant Foundation
P52 Comparison of Nodal Versus Primary Her2/neu Expression in Node-Positive Breast Cancer Patients
C.E. LagoToro,1* E. Grujic,2 A.R. Larsen,1 L. Allen,1
A.V. Barrio,1 B. Sieling,3 T. Fancher,3 T.G. Frazier.1
1. Department of Breast Surgery, The Bryn Mawr Hospital, Bryn Mawr, PA; 2. Department of Pathology, The Bryn Mawr Hospital, Bryn Mawr, PA; 3. Department of Breast Surgery, St. Mary's Hospital, Waterbury, CT.
P53 Validation of a Model to Predict Four or More Metastatic Axillary Nodes in Sentinel Node Positive Breast Cancer Patients
B. Zendejas,* A.C. Degnim, T.L. Hoskin, C.A. Reynolds,
D.R. Farley, J.C. Boughey. Mayo Clinic, Rochester, MN.
P54 Primary and Secondary Angiosarcoma of the Breast: A Review of 41 Cases
J.S. Scow,1* C.A. Reynolds,2 A.C. Degnim,1 I.A. Petersen,2
J.W. Jakub,1 J.C. Boughey.1 1. Gastrointestinal and General Surgery, Mayo Clinic, Rochester, MN; 2. Mayo Clinic, Rochester, MN.
P55 Effect of Paget’s Disease on Survival in Breast Cancer.
R. Layeequr Rahman,1* S. Crawford,2 N. Rudolph,1
M. Arredondo.1 1. Texas Tech University Health Sciences Center, Amarillo, TX; 2. UMass Medical School, Worcester, MA.
P56 Can Axillary Node Dissection Be Omitted in a Subset of Patients with Low Local and Regional Failure?
C. Barkley,1* J. Bellon,1 B. Smith,3 J. Wong,1 M. Gadd,3
A. Taghian,3 E. Winer,2 J. Iglehart,1 J. Harris,2
M. Golshan.1 1. Brigham and Women's Hospital, Boston, MA; 2. DanaFarber Cancer Institute, Boston, MA; 3. Massachusetts General Hospital, Boston, MA.
P57 Clinical Utility of Routine Radiologic-Pathologic Correlation of Percutaneous Breast Biopsy Specimens
Jernigan, B.K. Bednarski,* J.J. Yeh, D.W. Ollila,
KlauberDemore, K.D. Amos, C. Kuzmiak, M.O. Meyers. University of North Carolina, Chapel Hill, NC.
P58 Early Stage Breast Cancer in Elderly Women -Can Radiation Therapy Safely Be Withheld Outside of a Clinical Trial Setting?
S. Lillard,1* N. Watroba,1 A. Miller,2 S. Kulkarni,1 S. Edge.1
1. Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY; 2. Roswell Park Cancer Institute Department of Biostatistics, Buffalo, NY.
P59 An Objective Parameter for Evaluation of Lymphedema
J. Bulatova,* N.Z. Carp, J.L. Sabol, R.M. Ciocca,
R.D. Smink. general surgery, MLH, Wynnewood, PA.
P60 Sentinel Node Frozen Section for Breast Cancer: Should It Be Done?
M. Jamal,1* J. Rayment,1 S. Doi,3 A. Omeroglu,2
A. Meguerditchian,1 S.H. Meterissian.1 1. Department of Surgery, McGill University Health Center, Montreal, QC, Canada; 2. Department of Pathology, Montreal, QC, Canada; 3. Queensland University, Brisbane, QLD, Australia.
P61 Poorer Survival in Male Breast Cancer is Attributed to Early-Stage Disease
J.L. Gnerlich,1* S. Seelam,2 E. Kimbuende,2
A.D. Deshpande,1 D.B. Jeffe,1 J.A. Margenthaler.1
1. Department of Surgery, Washington University School of Medicine, Saint Louis, MO; 2. Saint Louis University School of Public Health, St. Louis, MO.
P62 Lymphatic Drainage Patterns from a Previously Treated Breast
I.M. Van der Ploeg,* H.S. Oldenburg, E.J. Rutgers,
M.J. Vrancken Peeters, B.B. Kroon, R.A. Valdés Olmos,
O.E. Nieweg. Surgery, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands.
P63 Alternative Therapy Used as Primary Treatment for Breast Cancer Negatively Impacts Outcome
E. Han,1* K. Steinbock,2 N. Johnson,2 N. Glissmeyer,2
T. DelaMelena,2 A. Wheeler.2 1. Surgery, OHSU, Portland, OR; 2. Legacy Health System, Portland, OR.
P64 Metaplastic Carcinoma (MPC) of the Breast: A Rare Entity with an Aggressive Clinical Course
D.X. Choi,* M. Worman, S. Safdar, L. ODonoghue,
X. Wang, C. Andrus, K.A. Skinner. Surgery, University of Rochester Medical Center, Rochester, NY.
P65 Predictive Value of BI-RADS Classification for Young Patients
G. Kennedy,* E. Avisar. Surgery/Surgical Oncology, University of Miami, Miami, FL.
P66 Is Surgical Excision Necessary for Radial Scars Diagnosed on Percutaneous Biopsy?
C. Mercado, A. Guth,* J. Cangiarella. Surgery, NYU School of Medicine, New York, NY.
P67 Meta-Analysis of Predictive Factors for Non Sentinel Lymph Node Metastases in Breast Cancer Patients with a Positive SLN
R.F. Van la Parra,1* P.G. Peer,2 M.F. Ernst,3 K. Bosscha.3
1 Surgery, Gelderse Vallei Hospital, Ede, Netherlands;
2 Radboud University Nijmegen Medical Center, Nijmegen, Netherlands; 3. Jeroen Bosch Hospital, Hertogenbosch, Netherlands.
P68 Significance of Fascin Expression in High Grade Breast Cancer
B. Chikman,* R. Lavy, G. Tolstov, L. Habler, A. Kapiev,
A. Halevy, J. Sandbank. Assaf Harofeh, Zerifin, Israel.
P69 Clinical Series of Oncoplastic Mastopexy to Optimize Cosmesis of Large Volume Resections for Breast Conservation
J. Bong,* R. Clapper, J. Parker, W.C. Dooley. Breast Institute, University of Oklahoma, Oklahoma City, OK.
P70 Cavity Shave Margins: Impact on Re-excision & Health Care Costs
A. Unzeitig,* A. Kobbermann, D. Euhus, A. Moldrem,
A.M. Leitch, J.V. Andrews, J. Huth, R. Rao. Surgery, University of Texas Southwestern Medical Center, Dallas, TX.
P71 Modern Breast Imaging Predicts Risk of Malignancy in Patients with Bloody Nipple Discharge
C.P. Bird,* N.K. Demore, D.W. Ollila, L.J. Tesche,
B.J. Calvo, K.D. Amos, M.O. Meyers. Dept of Surgery, University of North Carolina, Chapel Hill, NC.
P72 The Effect of Frozen Section Analysis on Detecting Micrometastases in Sentinel Lymph Nodes in Patients with Breast Cancer
E. Madsen,1* L. Smeets,1 T. Van Dalen,1 J. Van Dalen.2
1 Diakonessenhuis Utrecht, Utrecht, Netherlands;
2 Erasmus University, Rotterdam, Netherlands.
P73 The Utility of Natural Language Processing (NLP) in
Determining the Incidence of High Risk Breast Disease and the Subsequent Development of Breast Cancer
E. Kim, MD,* J. Sharko, Ph.D., B. Drohan, MS, C. Roche, NP, Y. Zhou, MD, M. Specht, MD, M. Gadd, MD,
B.L. Smith MD, Ph.D, K.S. Hughes, MD. Massachusetts General Hospital, Department of Surgical Oncology, Boston, MA.
P74 The Effect of Neoadjuvant Chemotherapy on Axillary Lymph Node Yield in Operable Breast Cancer Patients: A Review of the NCCN Database
Lee,1* R.L. Plews,2 J.V. Kiluk,1 N. Khakpour,1
Rawal,1 W.B. Carter,1 C. Laronga,1 L. Loftus.1
1. Comprehensive Breast Program, Moffitt Cancer Center, Tampa, FL; 2. University of South Florida College of Medicine, Tampa, FL.
P75 Simplified Prognostic Approach Predicting Disease Progression in Patients with High Grade Breast Cancer
B. Chikman, R. Lavy,* G. Tolstov, L. Habler,
S. Vasyanovich, J. Sandbank, A. Halevy. Assaf Harofeh Medical Center, Tel Aviv, Israel.
P76 Nipple-Areola Complex Sparing Mastectomy is Technically Feasible for Risk Reduction and Early-stage Breast Cancer
J. Wagner,1* R. Fearmonti,2 L. Pantoja,1 E. Beahm,3
M. Crosby,3 I. Bedrosian,1 K. Hunt,1 H. Kuerer,1 F. MericBernstam,1 M. Ross,1 B. Feig,1 A. Lucci,1 R. Hwang,1
S. Krishnamurthy,4 L. Feng,5 M. Hernandez,5 G. Babiera.1
1. MD Anderson Cancer Center, Department of Surgical Oncology, Houston, TX; 2. Duke University School of Medicine Division of Plastics and Reconstructive Surgery, Durham, NC; 3. MD Anderson Cancer Center, Department of Plastic Surgery, Houston, TX; 4. MD Anderson Cancer Center, Department of Pathology, Houston, TX; 5. MD Anderson Cancer Center, Department of Biostatistics, Houston, TX.
P77 Sentinel Lymph Node Biopsy in Patients with Breast Cancer Using Superparamagnetic Iron Oxide and a Magnetometer
M. Shiozawa,2* A. Lefor,1 Y. Hozumi,1 K. Kurihara,2
N. Sata,1 Y. Yasuda,1 M. Kusakabe.3 1. Surgery, Jichi Medical University, Tochigi, Tochigi, Japan; 2. Oyama Municipal Hospital, Oyama, Tochigi, Japan; 3. University of Tokyo, Tokyo, Japan.
P78 Contralateral Prophylatic Mastectomy in Breast Cancer Patients Who Test Negative for BRCA Mutations
M. HowardMcNatt,* R. Schroll, G. Hurt, E. Levine.
Surgery, Wake Forest Baptist Medical Center, WinstonSalem, NC.
P79 Breast Education in Residency
J.P. Wilson,* S. Edge. Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY.
Endocrine
P80 The Diagnosis of Parathyroid Cancer After Minimally Invasive Parathyroidectomy Does Not Mandate Further Open Radical Surgery
C.J. O'Neill,1* C. Chan,1 J. Symons,1 D.L. Learoyd,2 A. Gill,3
S.B. Sidhu,1 L.W. Delbridge,1 M.S. Sywak.1 1. University of Sydney, Endocrine Surgical Unit, Sydney, NSW, Australia;
1 Department of Endocrinology, Royal North Shore Hospital, St Leonards, Sydney, NSW, Australia;
2 Department of Pathology, Royal North Shore Hospital, St Leonards, Sydney, NSW, Australia.
P81 Laparoscopic Adrenalectomy for Metastatic Disease Improving Survival One Gland at a Time
E.J. Mitmaker,* M.R. Vriens, R.H. Grogan, A. Harari,
J. Gosnell, O.H. Clark, W.T. Shen, Q.Y. Duh. Endocrine Surgery, University of California, San Francisco, San Francisco, CA.
P82 Curative Surgery for Pancreatico-Duodenal Neuroendocrine Tumors: The Tel Aviv Experience
O. Zmora,* Y. Kariv, J. Klausner. Surgery, Tel Aviv Sourasky Medical Center, Ra'anana, Israel.
P83 Combination of Preoperative Ultrasonographic Mapping and Radioguided Occult Lesion Localization in Patients with Locally Recurrent/Persistent Papillary Thyroid Carcinoma
S. Gorgulu,* E. Ozturk, S. Ilgan, R. Yildiz, O. Emer,
A. Ayan, S. Deveci, E. Alagoz, M.A. Ozguven, T. Tufan.
Gulhane Military Medical Academy, Ankara, Turkey.
P84 Post Operative Thyroglobulin Level: Significant Marker of Recurrent Papillary Thyroid Carcinoma
R.C. Webb,* R.S. Howard, A. Stojadinovic, H.B. Burch.
Walter Reed Army Medical Center, Washington, DC.
P85 Population-Based Review of Gastrointestinal
Carcinoids
A. Aljahdali,1* C. De Gara,1 R. McEwen,2 S. Ghosh,3
D. Schiller.1 1. Department of Surgery, University of Alberta, Edmonton, AB, Canada; 2. Department of Radiation Oncology, Cross Cancer Institute, Edmonton, AB, Canada; 3. Department of Biostatistics, Alberta Health Services Cancer Care, Edmonton, AB, Canada.
P86 Initial CA19-9 Levels Predict Survival In Patients With Carcinoma of the Pancreatic Head, But Not Resectability
U. Von Holzen,* F. Zhu, J.C. Watson, J.P. Hoffman. Fox Chase Cancer Center, Philadelphia, PA.
P87 25-hydroxyvitamin D Status Does Not Affect Intraoperative Parathyroid Hormone Dynamics in Patients with Primary Hyperparathyroidism
J.T. Adler,* R.S. Sippel, H. Chen. University of Wisconsin, Madison, WI.
P88 Withdrawn
P89 Tyrosine Kinase Signaling in Malignant Pheochromocytoma/Paraganglinomas -Utilizing Sorafenib as a Therapeutic Agent
K. Idrees,1* J.S. Liles,2 M.B. Kraemer,2 A. Warriner,2
T.B. Vaughn,2 C. Arguello,2 F. Ovalle,2 R. Rosenthal,2
O. Hameed,2 J.P. Arnoletti,2 M.J. Heslin.2 1. Section of Surgical Oncology, Department of Surgery, University of Pittsburgh, Pittsburgh, PA; 2. University of Alabama at Birmingham, Birmingham, AL.
P90 The Effect of Parathyroidectomy on Hypertension in Patients with Primary Hyperparathyroidism
N. Samm,* B. Zarebczan, R.S. Sippel, H. Chen. University of Wisconsin, Madison, WI.
P91 Bilateral Neck Exploration For Primary Hyperparathyroidism: Is It Still Relevant?
R.A. Dilawari,* A. Porpiglia. Surgery, University of Tennessee Health Science Center, Memphis, TN.
P92 A Comparison of the Ligasure™and Harmonic Scalpel® in Thyroid Surgery: A Single Institution Review
B. Zarebczan,* D. Mohanty, H. Chen. University of Wisconsin, Madison, WI.
Disclosure: Consultant: Covidien
P93 Routine Vitamin D Supplementation Following Total Thyroidectomy: An Algorithm Based on “Morning After” Parathyroid Hormone Levels
A.K. Cayo,* T.S. Wang, J.S. Scheel, E.K. Krzywda,
S.D. Wilson, T.W. Yen. Surgery, Medical College of Wisconsin, Milwaukee, WI.
P94 Management of Follicular Thyroid Carcinoma Should be Individualized Based on Degree of Capsular and Vascular Invasion
C.J. O'Neill,1* L. Vaughan,1 D.L. Learoyd,2 S.B. Sidhu,1
L.W. Delbridge,1 M.S. Sywak.1 1. University of Sydney, Endocrine Surgical Unit, St. Leonards, Sydney, NSW, Australia; 2. Department of Endocrinology, Royal North Shore Hospital, St. Leonards, Sydney, NSW, Australia.
Gastrointestinal
P95 A Comparison of Competing Lymph Node Staging Schemes in Resectable Gastric Cancer
D.D. Smith,2* R.A. Nelson,2 R.E. Schwarz.1 1. UTSW Medical Center, Dallas, TX; 2. City of Hope Cancer Center, Duarte, CA.
P96 R0 Resection After Induction Gemcitabine/ Oxaliplatin/Cetuximab +/-Capecitabine-Based Chemoradiation For Locally Advanced Pancreatic Cancer
Esnaola,1* E. GarrettMayer,1 P. O'Brien,1 E.R. Camp,1
Thomas,1 D.J. Cole,1 S. Cole,1 U.B. Chaudhary,2
A.J. Montero,3 B. Hoffman,1 J. Romagnuolo,1 D.T. Marshall.1 1. Medical University of South Carolina, Charleston, SC; 2. University of California Fresno, Fresno, CA; 3. University of Miami, Miami, FL.
P97 Low-Dose Metronomic Gemcitabine Has High Antimetastatic Efficacy in an Orthotopic Mouse Model of Pancreatic Cancer
Tran Cao,1* M. Bouvet,1 E. Romney,2 S. Kaushal,1
Keleman,2 G. Kim,2 J. Fruehauf,2 D.K. Imagawa,2
R.M. Hoffman,3 M.H. Katz.2 1. UC San Diego, San Diego, CA; 2. Surgery, UC Irvine, Orange, CA; 3. AntiCancer, Inc., San Diego, CA.
P98 Intensity-Modulated Radiation Therapy in Hepatocellular Carcinoma and Cirrhosis: Evaluation of Radiological and Pathological Response
S. Samaniego,* C. Gimenez, U. Katta, R. Roccio,
C. Moorthy, S. BentleyHibbert, D. Wolf, M. RodriguezDavalos, M. Facciuto. Westchester Medical Center, New York, NY.
P99 Interferons Augment the Antitumoral Activity of Sorafenib in Human Pancreatic Cancer Cell Lines
N.R. Billimoria,1* A.A. Arora,1 S.S. Galoforo,2 B. Marples,2
G.D. Wilson,2 M.J. Jacobs.1 1. General Surgery, William Beaumont Hospital, Royal Oak, MI; 2. Radiation Oncology, William Beaumont Hospital, Royal Oak, MI.
P100 Adjuvant Gemcitabine and Erlotinib for Resected Pancreatic Cancer
P. Bao,1* R.K. Ramanathan,3 A.J. Moser,2 N. Bahary,2
B.C. Lembersky,2 D.L. Bartlett,2 S.J. Hughes,2 K.K. Lee,2
H.J. Zeh.2 1. Stony Brook University Hospital, Stony Brook, NY; 2. University of Pittsburgh Medical Center, Pittsburgh, PA; 3. TGen, Scottsdale, AZ.
P101 Multiplexed Cell Signaling Analysis of Normal Gastric ucosa, Gastric Metaplasia and Invasive Cancer eveals Distinctive Fingerprints of Gastric Cancer
E. Mammano,1* F. Galdi,1 E. Tessari,1 M. Briarava,1
A. Marchet,1 G.M. Rossi,1 P.L. Pilati,1 G. Esposito,2
M. Digito,1 F. Farinati,3 D. Nitti.1 1. Clinica Chirurgica 2, Department of Oncological and Surgical Sciences, Padova, Italy; 2. Oncology Section, Department of Oncology and Surgical Sciences, Padova, Italy; 3. Departments of Surgical and Gastroenterological Sciences, Padova, Italy.
P102 Tumor Size and Depth Predict Rate of Lymph Node Metastasis and Utilization of Lymph Node Sampling in Surgically Managed Gastric Carcinoids
M.S. Saund,1* R.H. Al Natour,1 Q. Huang,1 V.A. Boosalis,2
J.S. Gold.1 1. VA Boston Healthcare System/Brigham and Women's Hospital, West Roxbury, MA; 2. VA Boston Healthcare System/Boston University School of Medicine, West Roxbury, MA.
P103 Additional Prognostic Information of DUPAN-2/ Span-1 in CA19-9 Negative Pancreatic Carcinoma
K. Yamashita,* M. Waraya, M. Watanabe. Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.
P104 Anastomotic Complications Following Ivor Lewis Esophagectomy in Patients Treated with Neoadjuvant Chemoradiation Are Related to Radiation Dose to the Gastric Fundus
W.P. Ceelen,* C. Vande Walle, T. Boterberg, D. Van de Putte, Y. Van Nieuwenhove, P. Pattyn. Ghent University Hospital, Ghent, Belgium.
P105 Duodenal Adenocarcinoma: Clinicopathologic Analysis and Prognostic Implications
G.A. Poultsides,1* J.L. Cameron,1 E.A. Sugar,2 R. Tuli,3
J.M. Winter,1 R.H. Hruban,4 T.M. Pawlik,1 J.M. Herman,3
B.H. Edil,1 M.A. Choti,1 C.L. Wolfgang,1 R.D. Schulick.1
1. Department of Surgery, Johns Hopkins Hospital, Baltimore, MD; 2. Departments of Epidemiology and Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; 3. Department of Radiation Oncology & Molecular Radiation Sciences, Johns Hopkins Hospital, Baltimore, MD; 4. Department of Pathology, Johns Hopkins Hospital, Baltimore, MD.
P106 mir-675 is Overexpressed in Alpha-Fetoprotein-
Secreting Hepatocellular Carcinoma
Hernandez,* D. Shibata, B. Centeno, G. Bloom,
Fulp, D. Chen, C. Timme, S. McCarthy, M. Gruidl,
T. Yeatman. GI Oncology, Moffitt Cancer Center and Research Institute, Tampa, FL.
P107 Failure of Normalization of CA19-9 Following Resection for Pancreatic Cancer is Tantamount to Metastatic Disease
S.R. AbdelMisih,* E.C. Ellison, S. Melvin, C.R. Schmidt,
M. Bloomston, I. Hatzaras, P. Muscarella. Surgical Oncology, Ohio State University Medical Center/Arthur G. James Cancer Hospital, Columbus, OH.
P108 The Clinicopathological Significance of Genomic Aberrations of MicroRNA Locus in Colorectal Cancer Patients
S. Ishimaru,1* K. Mimori,1 M. Mori.2 1. Institute of Bioregulation, Kyushu University, Beppu, Oita, Japan;
2. Osaka University, Beppu, Osaka, Japan.
P109 Pancreas-Protocol Imaging at a High-Volume Center Leads to Improved Preoperative Staging of Pancreatic Ductal Adenocarcinoma
D.M. Walters,1* J.B. Stokes,1 E.E. De Lange,2 R.B. Adams,1
T.W. Bauer.1 1. University of Virginia, Department of Surgery, Charlottesville, VA; 2. University of Virginia, Department of Radiology, Charlottesville, VA.
P110 Improved Survival in Patients with Resected T1-3 N0-1 Pancreatic Adenocarcinoma Using Adjuvant Conformal or Intensity-Modulated Chemoradiation and Intravenous Gemcitabine
N. Hanna,* S. Yovino, N. Pandya, N. Horiba, P. Hausner,
P. Darwin, E. Goldberg, W. Regine, H. Alexander. Surgery, University of Maryland School of Medicine, Baltimore, MD.
P111 Clinical Significance of mir-125b Expression in Colorectal Cancer Patients
T. Yokobori,1* K. Mimori,1 H. Kuwano,2 M. Mori.3
1. Department of Surgery, Medical Institute of Bioregulation, Kyushu University, Beppu, Japan; 2. Gunma University, Maebashi, Japan; 3. Osaka University, Suita, Japan.
P112 Prophylactic Total Gastrectomy For Hereditary Diffuse
Gastric Cancer: Surgical and Pathological Results
P.K. Pandalai,1* D. Patel,4 D.C. Chung,2 G.Y. Lauwers,3
S.S. Yoon.5 1. Department of Surgery Massachusetts General Hospital, Boston, MA; 2. Department of Medicine Massachusetts General Hospital, Boston, MA;
3. Department of Pathology Massachusetts General Hospital, Boston, MA; 4. Center for Risk Analysis Massachusetts General Hospital, Boston, MA; 5. Division of Endocrine and Oncologic Surgery Hospital of the University of Pennsylvania, Philadelphia, PA.
P113 Adjuvant Therapy for Resectable Pancreatic Cancer: A Simple Prediction Rule
J.K. Smith,* S.C. Ng, J.P. Simons, Z. Zhou, S.A. Shah,
T.P. McDade, J.F. Tseng. Surgical Outcomes Analysis & Research, University of Massachusetts Medical School, Worcester, MA.
P114 Does Neoadjuvant Therapy Improve Survival in Patients with Resectable Pancreatic Cancer?
K.T. Papalezova,* V.M. Kim, S.S. Stinnett, D.G. Blazer III,
B.M. Clary, T.N. Pappas, D.S. Tyler, R.R. White. Surgical Oncology, DUMC, Durham, NC.
P115 The Novel Sigma-2 Receptor Ligand SW43 Induces Apoptosis in Pancreas Cancer
J.R. Hornick,* D. Spitzer, P.S. Goedegebuure, R.H. Mach,
W.G. Hawkins. Washington University School of Medicine, St. Louis, MO.
P116 Irreversible Electroporation of the Liver and Liver Hilum in Swine
K.P. Charpentier,* F. Wolf, M. Resnick, L. Noble, B. Winn,
D. Dupuy. Warren Alpert Medical School at Brown University, Providence, RI.
Disclosure: Grant/Research Support: AngioDynamics
P117 Prospective Whole Mount Analysis of Rectal Cancer Following Combined Modality Therapy: Long-Term Oncologic Outcome
J.J. Mezhir,* J.G. Guillem, J. Shia, E. Riedel, L.K. Temple, G.M. Nash, M.R. Weiser, P.B. Paty, W.D. Wong. Surgery, Memorial SloanKettering Cancer Center, New York, NY.
P118 Laparoscopic Liver Resection for Cirrhotic Patients with Hepatocellular Cancer: An Early Experience
F. Alemi,* C. Freise, S. Kang, R. Hirose, J. Roberts,
L. Stewart, C.U. Corvera. University of California, San Francisco, San Francisco, CA.
P119 Is Lymph Node Dissection With High Ligation Always
Necessary For Right Colon Cancer?
H. Kobayashi,* T. Higuchi, M. Enomoto, M. Yasuno,
H. Uetake, S. Iida, T. Yoshimura, T. Ishikawa, M. Ishiguro,
K. Sugihara. Department of Surgical Oncology, Tokyo Medical and Dental University, Tokyo, Japan.
P120 Functional Outcome and Stricture Rates with the Use of Circular Stapler for Esophagogastric Anastomosis after Esophagectomy
G. Pines,1* I. Sifrony,3 E. Melzer,2 Y. Klein,1
S. Machlenkin,1 V. Buyeviz,1 H. Kashtan.1 1. Surgery B, Kaplan Medical Center, Rehovot, Israel; 2. Kaplan Medical Center, Rehovot, Israel; 3. Hebrew University School of Medicine, Jerusalem, Israel.
P121 Role of Fecal Diversion for Low Rectal Cancer Resection
V.R. Kakarla,* S.J. Nurkin, K. Nandipati, H. Tiszenkel,
A. Castro, J. Turner. New York Hospital of Queens, Flushing, NY.
P122 Double Contrast-Enhanced Ultrasonography for the Preoperative Evaluation of Gastric Cancer: A Comparison to Endoscopic Ultrasonography with Respect to Histopathology
Z. Zheng,1* Y. Yu,1 M. Lu,1 W. Sun,1 F. Wang,1 P. Li,1
Y. Zhang,1 L. Lin,1 P. Wang,1 J. Chen,1 H. Zhang,1 Z. Xie,1
X.D. Dong.2 1. The Second Affiliated Hospital of Wenzhou Medical College, Wenzhou, Zhejiang, China; 2. Stamford Hospital Affiliate of Columbia University, Stamford, CT.
P123 Major Hepatic Resection for Hilar Cholangiocarcinoma (HC) -Has Long-Term Survival Changed?
G.M. Sclabas,* B.M. Dy, S. Khan, C.M. Lohse, K. Reid Lombardo, M.L. Kendrick, F.G. Que, M.B. Farnell,
J.H. Donohue, D.M. Nagorney. Dept. of Gastroenterologic and General Surgery, Mayo Clinic Rochester, Rochester, MN.
P124 Meta-Analysis of Trials Comparing Minimally Invasive and Open Liver Resections for Hepatocellular Carcinoma
A. Fancellu,1* A. Rosman,2 V. Sanna,3 G.R. Nigri,4
L. Zorcolo,5 M. Pisano,6 M. Melis.7 1. Department of Surgery Institute of Clinica Chirurgica, University of Sassari, Sassari, SS, Italy; 2. Section of Gastroenterology and Medicine Program, Mount Sinai School of Medicine and Bronx VAMC, New York, NY; 3. Department of Oncology, Azienda ASL n.1 Sassari, Sassari, SS, Italy;
4. Department of Surgery, Sapienza University of Rome, Roma, RM, Italy; 5. Department of Surgery, University of Cagliari, Cagliari, CA, Italy; 6. Department of Surgery, Ospedali Riuniti di Bergamo, Bergamo, BG, Italy;
7. Division of Surgical Oncology, New York University School of Medicine and NYHHS VAMC, New York, NY.
P125 IPMN-Associated Cancers, Family History; Genetic Predisposition?
N. Lubezky,1* M. BenHaim,1 R. Nackache,1
E. Brazowski,2 I. Solar,2 J.M. Klausner.1 1. Department General Surgery B, TelAviv Medical Center, TelAviv, Israel;
2. Institute of Pathology, TelAviv Medical Center, TelAviv, Israel.
P126 Prospective Trial of Diagnostic Peritoneal Lavage to Detect Positive Peritoneal Cytology in Patients with Advanced Gastric Cancer
K.K. Roggin,* M.D. McKee, J.J. Mezhir, E. Galka,
M.C. Posner. Surgery, University of Chicago, Chicago, IL.
P127 Single Institution Experience of 215 Patients Comparing Accuracy of Endoscopic Ultrasound with Subsequent Pancreatic Surgery
C. Boutros,* E.. Genova, M. Haniff, N. Toubia,
P. Somasundar, N.J. Espat. Division of Surgical Oncology, Roger Williams Medical Center, Providence, RI.
P128 Lymph Node Ratio is Inferior to pN-Stage in Predicting Outcome in Colon Cancer Patients with High Numbers of Analyzed Lymph Nodes
Viehl,1* A. Ochsner,1 U. Guller,1 R. Cecini,2 I. Langer,1
Terracciano,4 U. Laffer,2 D. Oertli,1 M. Zuber.3
1. Department of Surgery, University of Basel, Basel, Switzerland; 2. Department of Surgery, Spitalzentrum Biel, Biel, Switzerland; 3. Department of Surgery, Kantonsspital Olten, Olten, Switzerland; 4. Institute of Pathology, University of Basel, Basel, Switzerland.
P129 Do Physician Attitudes Influence Treatment Patterns for Pancreatic Cancer?
A. McKay, J. Lipschitz, J. Woodmass.* Surgery; Community Health Sciences, University of Manitoba, Winnipeg, MB, Canada.
P130 Thymidylate Synthase Expression Improves Clinical Risk Score Prediction of Recurrence and Survival After Hepatic Resection of Metastatic Colorectal Cancer
S.K. Maithel,1* M. Gonen,2 H. Ito,2 R.P. DeMatteo,2
P.J. Allen,2 Y. Fong,2 L.H. Blumgart,2 W.R. Jarnagin,2
M.I. D'Angelica.2 1. Surgical Oncology, Emory University, Atlanta, GA; 2. Memorial SloanKettering Cancer Center, New York, NY.
P131 Factors Predicting Response and Survival after Yttrium-90 Radioembolization of Unresectable Neuroendocrine Tumor Liver Metastases: A Critical Appraisal of 48 Cases
A. Saxena,1* D.L. Morris,1 T.C. Chua,1 L. Bester.2 1. UNSW Department of Surgery, St George Hospital, Sydney, NSW, Australia; 2. St Vincent's Hospital, Sydney, NSW, Australia.
P132 A Combination Approach to Enhance Taxane-Based Antitumor Activity in Experimental Pancreatic Cancer
N. Awasthi, A. Kirane,* M.A. Schwarz, R.A. Brekken,
R.E. Schwarz. UTSW Medical Center, Dallas, TX.
P133 Multicentric Study on Robotic Tumor-Specific Mesorectal Excision for the Treatment of Rectal Cancer
A. Pigazzi,1* A. Patriti,3 J.H. Baek,4 F. Biffi,2 J. GarciaAguilar,1 L. Casciola,3 F. Luca.2 1. General and Oncologic Surgery, City of Hope, Duarte, CA; 2. European Institute of Oncology, Milan, Italy; 3. Ospedale San Matteo degli Infermi, Spoleto, Italy; 4. Inha University College of Medicine, Incheon, South Korea.
Disclosure: Honorarium: Intuitive Surgical
P134 Radiolabeled Anti-CA 19-9 and Anti-CEA as PET Imaging Probes for Pancreas Cancer
M. Girgis,1* V. Kenanova,2 T. Olafsen,2 K. McCabe,2
A. Wu,2 J.S. Tomlinson.1 1. UCLA Department of Surgery, Los Angeles, CA; 2. UCLA Crump Institute for Molecular Imaging, Los Angeles, CA.
P135 Management of Colorectal Liver Metastases in the Elderly Patient: A Decision Analysis
S. Yang,1* S. Alibhai,1 E. Kennedy,1 N. Coburn,2 C. Law.2
1. University of Toronto, Toronto, ON, Canada; 2. Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
P136 Inaccuracy of Preoperative Classification of Pancreatic Cystic Neoplasms: Are We Improving?
A.J. Russ,* E.R. Winslow, R.J. Rettammel, S.M. Weber,
C.S. Cho. Section of Surgical Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI.
P137 Impact of Temporary Stoma on Quality of Life (QOL) of Rectal Cancer Patients Undergoing Treatment
H.B. Neuman,1* S. Patil,2 S. Fuzesi,2 W.D. Wong,2
M.R. Weiser,2 J.G. Guillem,2 P.B. Paty,2 G.M. Nash,2
K.N. Duhamel,2 L.K. Temple.2 1. Surgery, Division of Surgical Oncology, University of Wisconsin, Madison, WI;
2. Memorial SloanKettering Cancer Center, New York, NY.
P138 Angiogenin and Leptin: Potential Targets for the Palliation of Peritoneal Ascites
E.K. Cooley,* C.W. Lee, L.A. Lambert, B. Rajeshkumar,
A. Tran, S. Shah, N. Anwar, G.F. Whalen. University of Massachusetts Memorial Medical Center, Worcester, MA.
P139 Isolated Pelvic Perfusion as Neoadjuvant Therapy for Advanced/Unresectable Malignancy
H. Wanebo,1* J. Belliveau,1 E. Gustafson,2 M. DiSienna,3
G. Begossi.4 1. Landmark Medical Center, Woonsocket, RI;
2. Miriam Hospital, Providence, RI; 3. Berkshire Medical Center, Pittsfield, MA; 4. Roswell Park Cancer Institute, Buffalo, NY.
P140 Liver Resection for Metastatic Adrenocortical Carcinoma
R.T. Ripley,1* A. Mathur,1 C.D. Kemp,1 R.E. Royal,1
S.K. Libutti,1 S.M. Steinberg,2 B.J. Wood,3 U. Kammula,1
T. Fojo,4 I. Avital.1 1. Surgery Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD;
2. Biostatistics and Data Management Section, Office of the Clinical Director, Center for Cancer Research, National Cancer Institute, NIH, Rockville, MD; 3. Department of Radiology, Clinical Center, NIH, Bethesda, MD; 4. Medicine Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD.
P141 Withdrawn
P142 Use of Adjuvant Chemotherapy in Elderly Colorectal Cancer Patients: A Case-Control Study
A. Mathieson,1* P.F. Ridgway,1 Y.J. Ko,2 A.J. Smith.1
1. University of Toronto, Toronto, ON, Canada; 2. Odette Cancer Center, Sunnybrook Health Sciences Center, Toronto, ON, Canada.
* designated presenter
P143 Genes Mediating Wnt and FGF Signaling are Potential
Biomarkers of Diffuse-Type Gastric Cancer
P.S. Ray,1* S.P. Bagaria,1 C. Moran,1 A. Fleisig,1 M. ShinSim,2 X. Cui.3 1. Department of Surgical Oncology, John Wayne Cancer Institute, Santa Monica, CA; 2. Department of Biostatistics, John Wayne Cancer Institute, Santa Monica, CA; 3. Department of Molecular Oncology, John Wayne Cancer Institute, Santa Monica, CA.
P144 The ChemoFx Assay: Response of 31 Hepatopancreato-biliary Tumor Patients
K. Lau,* N. Agee, I.H. Mckillop, D. Sindram, J.B. Martinie,
D.A. Iannitti. Carolinas Medical Center, Charlotte, NC.
P145 Regionalization of Pancreatic Resection for Malignancy in NY State and the Effect of Hospital Volume on Perioperative Mortalit
D.D. Cox,* A. Miller, S. Edge, B. Kuvshinoff. Surgical Oncology, Roswell Park Cancer Institute, Buffalo, NY.
P146 Neoadjuvant Chemotherapy is Superior to Adjuvant Treatment in Resectable Pancreatic Adenocarcinoma
A. Artinyan,1* D. Anaya,1 B. Mailey,3 J.D. Ellenhorn,2
J. Kim.2 1. Baylor College of Medicine, Houston, TX; 2. City of Hope, Duarte, CA; 3. UC Irvine School of Medicine, Irvine, CA.
P147 Laparoscopic Liver Surgery in Cancer Patients: Experience at a National Cancer Center
R. Matteotti,* A. Gumbs, V. Siripurapu, J. Hoffman.
Surgical Oncology, Fox Chase Cancer Center,
Philadelphia, PA.
P148 Association of Tumor Biology and Neoadjuvant Therapy with Actual Five-Year Survival in Esophageal Carcinoma
T. Kim,* K. BenDavid, S.R. Grobmyer, S.B. Vogel,
S. Hochwald. Surgery, University of Florida College of Medicine, Gainesville, FL.
P149 Allogeneic Red Blood Cell Transfusion Following Pancreaticoduodenectomy for Ductal Adenocarcinoma is Associated with Earlier Recurrence and Reduced Survival
P.J. Kneuertz,* C.K. Chu, S.K. Maithel, J.M. Sarmiento,
K.A. Delman, C.A. Staley, D.A. Kooby. Department of Surgery, Emory University School of Medicine, Atlanta, GA.
P150 Pancreatic Resection is a Feasible Therapeutic Option for Elderly Patients
G.J. Lahat,* R. Sever, I. Nachmany, N. Lubezky, M. BenHaim, R. Nakache, J. Koriansky, J.M. Klausner. Sourasky Medical Center, Tel Aviv, Israel.
P151 Lymph Node Micrometastasis (Micromets) Correlated to Other Prognostic Factors in Colon Cancer (CCa)
S. Saha,* S. Sirop, M. Soni, A. Korant, B. Chakravarty,
S. Pampanagouda, D. Wiese. McLaren Regional Medical CenterMichigan State University, Flint, MI.
P152 Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Prevents Recurrence of Mucinous Ascites from Appendiceal Cancer
L.A. Lambert,1* K.F. Fournier,2 P.F. Mansfield.2 1. Surgical Oncology, UMass Memorial Medical Center, Worcester, MA; 2. MD Anderson Cancer Center, Houston, TX.
P153 Multimodality Management of Neuroendocrine Tumors Metastatic to the Liver
S. Celinski,* K.T. Nguyen, J.L. Steel, R. Mehra, J.W. Marsh,
D.A. Geller, A. Tsung, T.C. Gamblin. University of Pittsburgh, Pittsburgh, PA.
P154 Robotic Total Mesorectal Excision for Rectal Cancer. A Prospective Analysis of Oncological Safety and Short-Term Outcomes
P. Bianchi,1* C. Ceriani,1 A. Locatelli,1 G. Zampino,2
B. Andreoni.3 1. Minimally Invasive Surgery Unit, European Institute of Oncology, Milano, Italy; 2. Division of Medical Oncology. European Institute of Oncology, Milano, Italy; 3. Division of General and Laparoscopic Surgery. European Institute of Oncology, Milano, Italy.
P155 Multimodal Treatments for Liver Metastases from Melanoma: Experience of a Single Institution
P.L. Pilati,* E. Mammano, E. Tessari, M. Briarava,
G. Mattara, C.R. Rossi, D. Nitti. Clinica Chirurgica 2, Department of Surgical and Oncological Sciences, Padova, Italy.
P156 Splenectomy Ameliorates Hematologic Toxicity of Intraperitoneal Hyperthermic Chemotherapy.
R.D. Becher,* P. Shen, J.H. Stewart, G. Russell, T. Bradley,
E.A. Levine. General Surgery, Wake Forest University, WinstonSalem, NC.
P157 Radical Resection after Chemoradiation Therapy for Locally Recurrent Rectal Cancer (LRRC)
M. Ikeda,* M. Sekimoto, N. Haraguchi, I. Takemasa,
T. Mizushima, H. Ishii, H. Yamamoto, Y. Doki, M. Mori.
Department of Surgery, Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
P158 Is (Neo) Adjuvant Treatment Necessary in Stage II of Low-Rectal Cancer Patients Subjected to Abdominosacral Amputation of the Rectum (ASAR)?
M. Bebenek,1* W. Tupikowski,1 K. Cisarz,1 A. Balcerzak,1
L. Wojciechowski,1 A. Stankowska,1 R. Tarkowski,2
T. Sedziak,1 R. Szulc,1 B. Bednorz,1 B. Kapturkiewicz.1
1. 1st Department of Surgical Oncology, Regional Comprehensive Cancer Center, Wroclaw, Poland; 2. Department of Oncology, Wroclaw Medical University, Wroclaw, Poland.
P159 Management of Hemochromatosis Associated Hepatocellular Carcinoma
S.W. Cho,* J.W. Marsh, D.A. Geller, T.C. Gamblin.
Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA.
P160 Withdrawn
P161 Laparoscopic vs. Open Surgery for Rectal Cancer. A NSQIP Analysis
S. Nurkin,* R. Kakarla, D. Ruiz, R. Jeganathan, J. Turner,
H. Tiszenkel. New York Hospital Queens / Weill Cornell Medical College, Flushing, NY.
P162 Number of Nodes Examined and the 12 Gene Colon Cancer Recurrence Score Predict Recurrence in Stage II Colon Cancer in 2 Independent Studies.
Lavery,1* M.J. O'Connell,2 M. Lopatin,3 G. Yothers,4
ClarkLangone,3 F. Baehner,3 M. Lee,3 S. Shak,3
N. Wolmark.2 1. Cleveland Clinic, Cleveland, OH; 2. NSABP Foundation, Pittsburgh, PA; 3. Genomic Health, Inc., Redwood City, CA; 4. NSABP Biostat Center and University of Pittsburgh, Pittsburgh, PA.
Disclosure: Grant/Research Support: Genomic Health, Inc., Consultant: Genomic Health, Inc.
P163 Audit of a Single Institution Familial Adenomatous Polyposis Registry, 1971-2009
S. Dharmarajan,* G. Nandakumar, O. Wolff, S. Agarwal,
J.W. Fleshman, A.Y. Lin. Washington University, Saint Louis, MO.
P164 A Comparison of Hematologic Toxicity Profiles after Heated Intraperitoneal Chemotherapy with Oxaliplatin and Mitomycin-C
K.I. Votanopoulos,* P. Shen, J.H. Stewart, G. Russell,
E.A. Levine. Wake Forest University, Winston Salem, NC.
P165 Bowel Complications in Patients with Peritoneal Carcinomatosis of Appendiceal Origin Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
A. Sardi,* C. Omohwo, C.A. Nieroda, D.R. Holter,
N. Athas, V. Gushchin. Surgical Oncology, Mercy Medical Center, Baltimore, MD.
P166 Lymph Node Ratio and Recurrence in Sentinel Lymph Node Mapping vs. Conventional Surgery in Colon Cancer
M. Soni,* S. Saha, S. Sirop, A. Korant, B. Chakravarty,
A. Singla, S. Pampanagouda, D. Iddings, D. Weise.
McLaren Regional Medical CenterMichigan State
University, Flint, MI.
P167 Multi-Cycle Early Post-Operative Intraperitoneal Chemotherapy (EPIC) Following Cytoreductive Surgery for Appendiceal Neoplasms with Isolated Peritoneal Metastasis
P.L. Wagner,* D. Jones, A. Aronova, P.B. Paty, G.M. Nash.
Memorial Sloan Kettering Cancer Center, New York, NY.
P168 Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy Perfusion For Peritoneal Surface Malignancies: Effective, But at What Cost?
A. Shaligram,1* G. Mann,1 L. Mann.2 1. Surgery, University of Washington, Seattle, WA; 2. None, Seattle, WA.
P169 Incidence and Occurrence Pattern of Second Primary Malignancies After Resection of Rectal Carcinoid Tumors
K. Sato,1* T. Akasu,1 S. Yamamoto,1 T. Matsuda,2
S. Fujita,1 Y. Moriya,1 Y. Saito.2 1. Colorectal Surgery Division, National Cancer Center Hospital, Tokyo, Japan;
2. Endoscopy Division, National Cancer Center Hospital, Tokyo, Japan.
P170 Oncologic Efficacy of Minimally Invasive Esophagectomy (MIE) After Neoadjuvant Chemoradiotherapy (NT) in Esophageal Cancer
A.S. Khithani,* D. Christian, J.G. Barton, J. Jay, D. Jeyarajah. Methodist Dallas Medical Center, Dallas, TX.
P171 The Delivery and Timing of Radiation Therapy Impact Survival in Patients with Rectal Adenocarcinoma
Y. Akmal,1* A. Artinyan,2 B. Mailey,1 W. Lee,1
S. Christopher,1 S.P. Mckenzie,1 A. Pigazzi,1 J. GarciaAguilar,1 J. Kim.1 1. General Oncologic Surgery, City of Hope National Medical Center, Duarte, CA; 2. Baylor College of Medicine, Michael E. Debakey VA Medical Center, Houston, TX.
P172 Hyperthermic Chemotherapy for Ovarian Cancer Report of the HYPERO Registry
C. Helm,1* S.D. Richard,2 J. Pan,1 D. Bartlett,3
M.D. Goodman,4 R. Hoefer,5 S.S. Lentz,6 E.A. Levine,7
B.W. Loggie,8 D.S. Metzinger,1 B. Miller,6 J.E. Spellman,9
P.H. Sugarbaker,10 S.N. Rai,1 R.P. Edwards.2 1. James Graham Brown Cancer Center, Louisville, KY; 2. MageeWomen's Hospital, Pittsburgh, PA; 3. Division of Surgical Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA; 4. Division of Surgical Oncology, Tufts Medical Center, Boston, MA; 5. Surgical Oncology Associates, Newport News, VA; 6. Division of Gynecologic Oncology, Wake Forest University, WinstonSalem, NC;
7. Division of Surgical Oncology, Wake Forest University, WinstonSalem, NC; 8. Division of Surgical Oncology, Creighton University, Omaha, NE; 9. Oncologic Surgery, Beebe Medical Center, Rehoboth Beach, DE; 10. Washington Hospital Center, Washington, DC.
Disclosure: Grant/Research Support: Thermasolutions Inc., Grant/Research Support: SanofiAventis
P173 Open Thermo-Surgical Ablation of Inoperable Primary Or Recurrent/Metastatic Abdomino-Pelvic Malignancies
C. Gajdos,* M.D. McCarter, N.W. Pearlman. University of Colorado, Aurora, CO.
P174 The Impact of Metastatic Lymph Node Ratio on Survival in Node-Positive Colon Cancer
S. Bordoli,2* S.S. Kukreja,2 J. Velasco,1 T.J. Hieken.3
1. Surgery, NorthShore University Health System Skokie Hospital, Skokie, IL; 2. Rush University Medical Center, Chicago, IL; 3. Rush Medical College, Chicago, IL.
P175 Gene Expression Profile Related to Cisplatin Intrinsic Resistance Using Our Established Anal Canal Squamous Cell Lines
A. Takeda.* Digestive Surgery, International University of Health and Welfare Hospital, Tochigi, Japan.
P176 Neoadjuvant and Adjuvant Therapy Does Not Improve Survival in Resected Biliary Cancers
E.S. Glazer,* V.G. Ellis, E.K. Abdalla, J.N. Vauthey,
S.A. Curley. Surgical Oncology, MD Anderson Cancer Center, Houston, TX.
P177 Risk-Adjustment Models In Assessing Postoperative Mortality Following Transthoracic Esophagectomy in Patients with Esophageal Cancer
D.J. Bosch,1* B.B. Pultrum,1 G.H. De Bock,2
J.K. Oosterhuis,3 M.G. Rodgers,3 J.T. Plukker.1 1. Dept Surgical Oncology, University Medical Center Groningen, Groningen, The Netherlands; 2. University Medical Center Groningen, Dept. of epidemiology, Groningen, The Netherlands; 3. University Medical Center Groningen, Dept. of anesthesiology, Groningen, The Netherlands.
P178 Pre-Operative Anemia Decreases Survival After Esophagectomy for Cancer
M. Melis,1* K.L. Meredith,2 S. Hoffe,2 R. Shridar,2
J.M. McLoughlin,3 J.M. Weber,2 R.C. Karl.2 1. Surgery, New York University, New York, NY; 2. Moffitt Cancer Center, Tampa, FL; 3. Medical College of Georgia, Augusta, GA.
P179 Severe Electrolyte Disturbances After Hyperthermic Intraperitoneal Chemotherapy: Oxaliplatin Versus Mitomycin C
N.M. Rueth,1* S. Murray,1 S. Huddleston,1 A. Abbott,1
E. Greeno,2 M.N. Kirstein,3 T.M. Tuttle.1 1. University of Minnesota Department of Surgery, Minneapolis, MN;
2. University of Minnesota Department of Medicine, Minneapolis, MN; 3. University of Minnesota College of Pharmacy, Minneapolis, MN.
P180 Cytoreduction and Hyperthermic Intraperitoneal Chemoperfusion in Women with Heavily Pretreated Recurrent Ovarian Cancer
W.P. Ceelen,* Y. Van Nieuwenhove, S. Van Belle,
H. Denys, P. Pattyn. Ghent University Hospital, Ghent, Belgium.
P181 Impact of Tumor Grade on Prognosis in Pancreatic Cancer: Should We Include Grade in AJCC Staging?
N. Wasif,1* C.Y. Ko,2 J. Farrell,2 Z. Wainberg,2 O.J. Hines,2
H. Reber,2 J.S. Tomlinson.3 1. Surgery, John Wayne Cancer Institute, Santa Monica, CA; 2. David Geffen School of Medicine at UCLA, Los Angeles, CA; 3. Greater Los Angeles VA Healthcare System, Los Angeles, CA.
P182 Comprehensive Pathologic Assessment of Pancreaticoduodenectomy Specimens
A. Sasson,* C. Are, A. Lazenby, Q. Ly. Univ of Nebraska Medical Center, Omaha, NE.
P183 Role of Laparoscopy in Neo-Adjuvant Therapy for Pancreatic Adenocarcinoma
A. Sasson,* C. Are, Q. Ly. Univ of Nebraska Medical Center, Omaha, NE.
P184 Single Incision Colectomy for Colon Cancer
M.E. McNally,1* B.T. Moore,2 K.M. Brown.2 1. General Surgery, University of MissouriKansas City, Kansas City, MO; 2. St. Luke's Hospital, Kansas City, MO.
P185 The Evolution of Surgical Management of Ampullary Adenomas: Evaluation of a Systematic Approach in the Era of Endoscopic Ultrasound
J.A. Breaux.* Surgical Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA.
P186 Tumor Location Does Not Impact Survival After Resection for Pancreatic Adenocarcinoma Despite Larger Tumors in the Tail
P. Toomey,* J. Hernandez, C.A. Morton, S. Dahal, S. Ross,
L. Barry, A. Roddenbery, A. Rosemurgy. University of South Florida, Tampa, FL.
P187 Laparoscopic Radiofrequency Thermal Ablation of Hepatocellular Cancer: Predictors of Survival
H. Akyildiz, J. Mitchell, A. Siperstein, E. Berber.*
Cleveland Clinic, Cleveland, OH.
P188 Pathologic Non-Responders After Neoadjuvant Chemoradiation for Esophageal Cancer Demonstrate No Survival Benefit Compared to Patients Treated with Primary Esophagectomy
Dittrick,* K. Turaga, J.M. Weber, R. Shridar, S. Hoffe,
Melis, J. Barthel, E. Eikman, M. Biagioli, R.C. Karl,
K.L. Meredith. H. Lee Moffitt Cancer Center, Tampa, FL.
P189 Laparoscopic Implantation of Radiofrequency Emitting Transponders in Stage III Pancreatic Tumors to Facilitate Radiation Therapy
S. Singla,1* J.L. Gates,1 J. Plastaras,2 N. Vapiwala,2
J.M. Metz,2 J.A. Drebin.1 1. Surgery, University Of Pennsylvania, Philadelphia, PA; 2. Radiation Oncology, University of Pennsylvania, Philadelphia, PA.
P190 Does the Clinical Outcome Following Resection for
Esophageal Cancer Treated with Neoadjuvant Chemoradiotherapy More Closely Follow the Initial or Post-Treatment Stage?
V.P. Koshenkov,* N. O'Donnell, M.W. Widmann,
A.H. Chevinsky. Surgery, Morristown Memorial Hospital, Morristown, NJ.
P191 Polymorphism of the Tandem Repeat Sequence in the Thymidylate Synthase Gene is Associated with Tumor Stage in Colon Cancer
S. Aguiar,* E.H. Olivieri, G. Baiocchi, F.O. Ferreira,
B.M. Rossi, D. Carraro, A. Lopes. Department of Pelvic Surgery, AC Camargo Cancer Hospital, Sao Paulo, Brazil.
P192 Fat Distribution and Quantity Predict Survival in Men with Rectal Cancer
C. Balentine,1* C. Robinson,1 C. Marshall,1 J. Wilks,1
K. Haderxhanaj,2 J. Enriquez,1 V. Bansal,1 S. Sansgiry,2
N. Petersen,2 A. Artinyan,1 S. Awad,1 D. Albo,1
D.H. Berger.1 1. Baylor College of Medicine, Houston, TX;
2. Michael E DeBakey Veterans Affairs Hospital, Houston, TX.
P193 Survival after Hepatic Resection with or without Intra-Hepatic Chemotherapy in Non Colorectal Liver Metastasis
M. Soni,* B. Chakravarty, A. Korant, S. Sirop, D. Wiese,
S. Nagpal, T. Singh, S. Saha. McLaren Regional Medical CenterMichigan State University, Flint, MI.
P194 Radiofrequency Ablation as Regional Management of Breast Cancer Liver Metastases
M.A. Cassera, C. Hammill, R. Wolf, L.L. Swanstrom,
P.D. Hansen.* Hepatobiliary and Pancreatic Surgery Program, Portland Providence Medical Center, Portland, OR.
P195 Peri-Operative Blood Pressure as a Risk Factor for Anastomotic Leakage in Colorectal Surgery
K. Noordzij, I. Grossmann, W. Mastboom, J. Klaase,
M. Lutke Holzik.* Surgery, Medisch Spectrum Twente, Enschede, Netherlands.
P196 Major Liver Resection in the Elderly; Is It Safe?
S.W. Cho,* A. Tsung, D.A. Geller, J.W. Marsh,
T.C. Gamblin. Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA.
P197 Mortality Within Twelve Months After Subtotal Esophagectomy for Cancer
G. Pines,1* V. Buyeviz,1 S. Machlenkin,1 Y. Klein,1
E. Idelevich,2 H. Kashtan.1 1. Surgery B, Kaplan Medical Center, Rehovot, Israel; 2. Kaplan Medical Center, Rehovot, Israel.
P198 Individual Surgeon, Pathologist and Other Factors Affecting Lymph Node Harvest in Stage II Colon Carcinoma. Is a Minimum of 12 Examined Lymph Nodes Sufficient?
L. Stocchi,* V.W. Fazio, I. Lavery, J. Hammel. Cleveland Clinic, Cleveland, OH.
P199 Right vs. Left Colon Cancer-Distinct Tumors?
I. Gatot, Z. Shapira, R. Lavy,* B. Chikman, A. Halevy.
Assaf Harofeh Medical center i, Tel Aviv, Israel.
P200 Tissue Factor Is Associated with a Prothrombotic State in Pancreaticobiliary Cancer (PBC)
A.V. Patel,1* A.A. Khorana,2 A. Bharthuar,3
B.W. Kuvshinoff,3 N. Mackman,4 A. Hutson,3 R.V. Iyer.3
1. Arizona Cancer Center, Tucson, AZ; 2. James P. Wilmot Cancer Center, Rochester, NY; 3. Roswell Park Cancer Institute, Buffalo, NY; 4. University of North Carolina at Chapel Hill, Chapel Hill, NC.
P201 Clinicopathological Determinants of Survival after Hepatic Resection of Hepatocellular Carcinoma in 97 Patients -Experience From an Australian Hepatobiliary Unit
T.C. Chua,* A. Saxena, F. Chu, W. Liauw, A. Kokandi,
J. Zhao, D.L. Morris. UNSW Department of Surgery, St George Hospital, Sydney, NSW, Australia.
P202 Survival Benefit Associated With Surgery Performed By a Colorectal Cancer Surgeon in a Cohort of Stage III Colon Cancer Patients Aged 65 and Older: An Analysis Using SEER-Medicare Data.
N.N. Hanna,1* E. Onukwugha,2 D. Mullins.2 1. Surgery, University of Maryland, Baltimore, MD; 2. University of Maryland, School of Pharmacy, Baltimore, MD.
Disclosure: Grant/Research Support: Sanofi Aventis
P203 Role of Radiation Therapy and Lymphadenectomy in Outcomes for Patients with Rectal Cancer: Are We Under Treating the Elderly?
N.L. Solomon,* S. Misra, M. Del Mazo, Y. Zhuge,
L.G. Koniaris. Surgical Oncology, University of Miami, Miami, FL.
P204 Surgical Management of Colorectal Cancer in Octogenarian and Nonagenarian Patients
B.A. Mailey,1 M. Yamamoto,1* A. Artinyan,2 A. Pigazzi,1
A. Hurria,1 S. Bhatia,1 J. GarciaAguilar,1 J. Kim.1 1. City of Hope, Duarte, CA; 2. Baylor College of Medicine, Houston, TX.
P205 Nodal Involvement as a Prognostic Factor for Stage IV Colon Cancer with or without Sentinel Lymph Node Mapping
S. Sirop,* S. Saha, A. Korant, M. Soni, M. Arora,
B. Chakravarty, D. Wiese, D. Eilander, S. Nagpal, T. Singh.
McLaren Regional Medical CenterMichigan State
University, Flint, MI.
P206 Body Fat Distribution is Associated with Oncologic Outcomes of Total Mesorectal Excision for Rectal Adenocarcinoma
N. Ballian,* M.G. Lubner, A. Munoz, C.P. Heise,
G.D. Kennedy. University of Wisconsin, Madison, WI.
P207 The Outcome of Sphincter Preservation and Abdomino-perineal Resection Following Preoperative Chemoradiation in Locally Advanced Low Rectal Cancer
W.M. Gawad,* M.M. Khafagy, S.M. Moneib. Surgical Oncology, National Cancer Institute, Cairo, Egypt.
P208 Various Prognostic Nodal Factors, Adjuvant Chemotherapy and Survival Among Same Cohort of Colon Cancer Patient Aged 65 and Older: An Analysis Using SEER-Medicare Data
N.N. Hanna,1* E. Onukwugha,3 M. Choti,2 A. Davidoff,3
I. Zuckerman,3 V. Hsu,3 D. Mullins.3 1. Surgery, University of Maryland, Baltimore, MD; 2. Johns Hopkins University, Baltimore, MD; 3. University of Maryland, School of Pharmacy, Baltimore, MD.
Disclosure: Grant/Research Support: Sanofi Aventis
P209 Actionable Indicators for Short and Long Term Outcomes in Rectal Cancer
J.T. Plukker,1* M. Gort,3 M. Broekhuis,4 N.S. Klazinga,4
R. Otter.2 1. Dept Surgical Oncology, University Medical Center Groningen, Groningen, The Netherlands;
2. Comprehensive Cancer Centre North East, Groningen, Groningen, Netherlands; 3. Faculty of Economics and Business, University of Groningen, Groningen, The Netherlands; 4. Department of Social Medicine, University of Amsterdam, Amsterdam, The Netherlands.
P210 Improper Wound Healing Does Not Limit the Application of Abdominosacral Amputation of the Rectum (ASAR) in Low-Rectal Cancer Patients
M. Bebenek,1* W. Tupikowski,1 K. Cisarz,1 A. Balcerzak,1
L. Wojciechowski,1 A. Stankowska,1 M. Pudelko,1
R. Tarkowski,2 T. Sedziak,1 R. Szulc,1 B. Bednorz,1
B. Kapturkiewicz.1 1. 1st Department of Surgical Oncology, Regional Comprehensive Cancer Center, Wroclaw, Poland; 2. *Department of Oncology, Wroclaw Medical University, Wroclaw, Poland.
P211 Impact of Lymph Node Status on Survival in Patients with Resected Stage IV Colon Cancer
S.P. Bagaria,1* P. Ray,1 R.W. Beart,2 D.A. Etzioni.2
1. Department of Surgical Oncology, John Wayne Cancer Institute, Santa Monica, CA; 2. Department of Colorectal Surgery, Keck School of Medicine, University of Southern California, Los Angeles, CA.
P212 Withdrawn
P213 Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Varying Histology – Aggressive But Safe
R. Wong,* G. Jibara, F. Manizate, Y. Assadipour, S. Hiotis,
S. Roayaie, M. Schwartz, D. Labow. Surgery, Mount Sinai School of Medicine, New York, NY.
P214 Pancreatic Resection in the 9th Decade of Life: Not Always a Safe Option for Pancreatic Malignancy
I. Hatzaras,* C. Schmidt, P. Muscarella, W.S. Melvin,
E.C. Ellison, M. Bloomston. Surgery, OSU, Columbus, OH.
P215 Perioperative Biochemical Tests Predict Perioperative and Disease-Related Mortality Following Pancreaticoduodenectomy
J. Coates,* E. Brown, J. Russo, S. Chen, R. Canter, R. Bold.
UC Davis, Sacramento, CA.
P216 Feasibility and Safety of Laparoscopic Complete Mesocolic Excision for Right Colon Cancer
T. Akasu,* S. Yamamoto, K. Sato, T. Funada, S. Fujita,
Y. Moriya. Colorectal Surgery Division, National Cancer Center Hospital, Tokyo, Japan.
P217 Sphincter Preservation and Local Recurrence Using a Multimodal Algorithm for Treatment of Surgically Difficult Rectal Cancer
R.J. Aragon,1* G.R. Machado,2 I.J. Kuo,2
A. Coutsoumpos,3 K.B. Zmaj,1 M.E. Reeves.1 1. Surgical Oncology, Jerry L. Pettis Memorial VA Medical Center, Loma Linda, CA; 2. Loma Linda University Medical Center, Loma Linda, CA; 3. Loma Linda University School of Medicine, Loma Linda, CA.
P218 Comorbidites Should Not Preclude Resection in Esophageal Cancer: The Role of Minimally Invasive Esophagectomy
D. Christian,* A.S. Khithani, J.G. Barton, J. Jay,
D. Jeyarajah. Methodist Dallas Medical Center, Dallas, TX.
P219 90% Hepatectomy with a Porto-Hepatic Shunt in a Canine Model: A Feasibility Study
S.T. Steen,* W. Conway, C. Guerra, M. Shin, G. Singh.
John Wayne Cancer Institute, Santa Monica, CA.
P220 Does a Preoperatively Placed Percutaneous Endoscopic Gastrostomy Tube Impact Negatively on Eventual Esophagectomy?
S.M. Foster,* M.H. Chung. Grand Rapids Medical Education and Research Center, Grand Rapids, MI.
P221 The Learning Curve in Robotic Gastrointestinal Surgery
A. Zemlyak,* P.Q. Bao, K.T. Watkins. Surgery, SUNY Stony Brook, Stony Brook, NY.
P222 Sub-optimal Removal of Lymph Nodes for Malignant Colonic Polyps and Impact on Survival in the General Population
N. Wasif,1* M.A. Maggard,2 J.S. Tomlinson,2 C.Y. Ko.2
1. Surgery, John Wayne Cancer Institute, Santa Monica, CA; 2. David Geffen School of Medicine at UCLA, Los Angeles, CA.
P223 Yttrium-90 Radiotherapy for Unresectable Intrahepatic Cholangiocarcinoma: A Preliminary Assessment of this Novel Treatment Option
A. Saxena,1* L. Bester,2 T.C. Chua,1 D.L. Morris.1 1. UNSW Department of Surgery, St George Hospital, Sydney, NSW, Australia; 2. St Vincent's Hosptial, Sydney, NSW, Australia.
Head & Neck
P224 Sentinel Node Biopsy Combined with Detection of Micrometastasis in Carcinoma of the Buccal Mucosa
M. Pandey,* U. Gaud, M. Shukla, S. Karthikeyan, |
M. Kumar. Surgical Oncology, Institute of Medical Sciences, Varanasi, UP, India.
P225 Iodine Inhibits the Growth of Thyroid Cancer Cells via Cell Cycle Arrest and Mitochondrial-mediated Apoptosis
G.G. Chen,* X.H. Liu, A.C. Vlantis, C.A. Van Hasselt. The Chinese University of Hong Kong, Hong Kong, China.
P226 Cervical Lymph Node Dissection for Metastatic Testicular Cancer
M.G. Van Vledder,1* J.A. Van Der Hage,2 W.J. Kirkels,1
C. Verhoef,1 J.W. Oosterhuis,1 J.H. De Wilt.3 1. Erasmus MC Daniel den Hoed Cancer Centre, Rotterdam, Netherlands; 2. Netherlands Cancer Institute AVL, Amsterdam, Netherlands; 3. UMC St. Radboud, Nijmegen, Netherlands.
Melanoma
P227 Accuracy and Predictive Value of Diagnostic Biopsy in Cutaneous Melanoma
C. Fusco,2* J. Boll,3 J.E. Jones,2 T.J. Hieken.1 1. Surgery, NorthShore University Health System Skokie Hospital, Skokie, IL; 2. Rush University Medical Center, Chicago, IL;
3. Rush Medical College, Chicago, IL.
P228 Patterns of Recurrence in Melanoma and the Impact on Survival
N. De Rosa,* J.E. Herndon II, J. Marcello, D.S. Tyler,
R.P. Scheri, S.K. Pruitt, J.L. Wheeler, A.P. Abernethy. Duke University Medical Center, Durham, NC.
Disclosure: Other: Pfizer, Inc.
P229 Adoptive Immunotherapy Using Effector T Cells Rendered Insensitive To TGF Signaling
J. Quatromoni, R.C. Koya, Y. Wang, J. Treger,
J. Economou.* Surgery, UCLA, Los Angeles, CA.
P230 Mitf Expression is Associated with Improved Survival in Melanoma
G.I. Salti,* K. Schaeffer. Surgical Oncology, University of Illinois at Chicago, Chicago, IL.
P231 Sentinel Lymph Node Biopsy (SLNB) is a Powerful Predictor of Recurrence for Patients with Cutaneous Head and Neck Melanoma (CHNM)
R.S. Sweeting,1* E.D. Routh,2 M.O. Meyers,2 P. Long,2
J.S. Frank,2 K.B. Stitzenberg,2 K.D. Amos,2 D.W. Ollila,2
J.J. Yeh.2 1. UNC Chapel Hill Department of Surgery, Chapel Hill, NC; 2. Lineberger Comprehensive Cancer Center, Chapel Hill, NC.
P232 Role of Sentinel Lymph Node Biopsy in Anorectal Melanoma
P.F. McAuliffe,1* J.E. Gershenwald,1 J.E. Lee,1
B.D. Badgwell,2 M.T. Ballo,3 J.N. Cormier,1 P.F. Mansfield,1
G.J. Chang,1 G.K. Zagars,3 E.R. Camp,4 M.I. Ross.1
1. Surgical Oncology, MD Anderson Cancer Center, Houston, TX; 2. University of Arkansas, Little Rock, AR;
3. Radiation Oncology MD Anderson Cancer Center, Houston, TX; 4. Medical University of South Carolina, Charleston, SC.
P233 Electrochemotherapy: Clinical Outcome and Predictive Factors from a Single Institution Experience on 50 Melanoma Patients
Campana,1* S. Pasquali,1 M. Basso,2 S. Mocellin,1
Vecchiato,3 V. Chiarion Sileni,4 L. Corti,2 D. Nitti,1
C.R. Rossi.3 1. Dpt. of Oncological & Surgical Sciences, University of Padova, Padova, Italy; 2. Radiotherapy, Istituto Oncologico Veneto, IRCCS, Padova, Italy;
3. Melanoma and Sarcoma Unit, Istituto Oncologico Veneto, IRCCS, Padova, Italy; 4. Medical Oncology, Istituto Oncologico Veneto, IRCCS, Padova, Italy.
P234 Preoperative Ultrasound Is Not Useful for Identifying
Nodal Metastasis in Melanoma Patients Undergoing
Sentinel Lymph Node Biopsy
C.Y. Chai,* J.S. Zager, S.S. Marzban, R.M. Rossi,
M. Szabunio, V.K. Sondak. Cutaneous Program, Moffitt Cancer Center, Tampa, FL.
P235 Novel Hand Held Intraoperative Radionuclide Imaging
D.L. Johnson,* P.D. Olcott, G. Pratx, C.S. Levin. Stanford University, Palo Alto, CA.
P236 Metastasectomy Improves Survival in Patients With Stage IV Melanoma; Time for a Second Look?
N. Wasif,* S.P. Bagaria, P. Ray, D.L. Morton. Surgery, John Wayne Cancer Institute, Santa Monica, CA.
P237 Age Disparities in Melanoma Treatment and Outcomes in the US
A. Zemlyak,* P. Pugliani, H. Meng, C.R. Pameijer. Surgery, SUNY at Stony Brook, Stony Brook, NY.
P238 Desmoplastic Melanoma – The Step-Child in the Melanoma Family?
N. Wasif,* R.J. Gray, B.A. Pockaj. Mayo Clinic Scottsdale, Phoenix, AZ.
P239 Primary Tumor Staining with ODAM, a Novel Biomarker, Is Predictive for Stage III Melanoma
S. Siddiqui,1* S.S. Gandhi,1 C.T. Bruker,2 K.D. Gray,1
J.L. Bell,1 D. Kestler,3 J.M. Lewis.1 1. Department of Surgery, University of Tennesse, Knoxville, TN;
2. Department of Pathology, University of Tennessee, Knoxville, TN; 3. UT Human Cancer and Immunology Program, Knoxville, TN.
P240 Bevacizumab Augmentation of Regional Melphalan in a Melanoma Xenograft Model
J.C. Padussis,1* H. Toshimitsu,2 C. Augustine,2 D.S. Tyler.1
1 General Surgery, Duke University, Durham, NC;
2 Durham VA Medical Center, Durham, NC.
P241 Predictors of Morbidity of Inguinal Lymph Node Dissection in Patients with Melanoma
T. Kingham,* G. Karakousis, K. Panageas, C.E. Ariyan,
M.S. Brady, D.G. Coit. Surgery, Memorial SloanKettering Cancer Center, New York, NY.
P242 Can Lymphatic Drainage Patterns of Head and Neck Melanoma be Predicted?
J.D. Jensen,1* R.J. Gray,2 N. Wasif,2 M.C. Roarke,2 W.J. Casey,2 P. Kreymerman,2 B.A. Pockaj.2 1. Midwestern University, Glendale, AZ; 2. Mayo Clinic, Scottsdale, AZ.
P243 Brain Metastases in Cutaneous Head and Neck Melanoma
A.M. Huismans,* K.F. Shannon. Melanoma Institute Australia, Sydney, NSW, Australia.
P244 Melanoma Pathology in the Community Setting: Are We Meeting the NCCN Minimum Reporting Criteria?
J. Fox,* A. Loeb, J. Ouellette, P. Termuhlen, M. Hellan.
Surgery, Wright State University, Dayton, OH.
P245 Completion Lymph Node Dissection In Melanoma Patients with a Tumor-Positive Sentinel Node Does Not Increase the Rate of Local-Regional Recurrences
H.J. Veenstra,* I.M. Van der Ploeg, M.W. Wouters,
B.B. Kroon, O.E. Nieweg. Surgery, Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, NoordHolland, Netherlands.
P246 Clinical Value of Radiographic Staging in Patients Diagnosed with AJCC Stage III Melanoma
P.K. Pandalai,1* F.J. Dominguez,3 J. Michaelson,2
K.K. Tanabe.1 1. Division of Surgical Oncology; Department of Surgery, Massachusetts General Hospital, Boston, MA; 2. Division of Surgical Oncology; Department of Pathology, Massachusetts General Hospital, Boston, MA; 3. Surgical Oncology Department, School of Medicine, Pontificia Universidad Catolica de Chile, Santiago, Chile.
P247 Natural History of Patients with Stage III Melanoma of Unknown Primary
G.C. Karakousis,1* S. Katz,2 K. Panageas,1 C. Ariyan,1
M.S. Brady,1 D. Coit.1 1. Memorial SloanKettering Cancer Center, New York City, NY; 2. Roger Williams Medical Center, Providence, RI.
P248 Utility of Pre-Operative 18F-FDG PET/CT and Brain MRI in Melanoma Patients with Palpable Lymph Node Metastases
T.S. Aukema,* R.A. Valdés Olmos, M.W. Wouters,
W.M. Klop, B.B. Kroon, W.V. Vogel, O.E. Nieweg.
Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands.
P249 Synchronous Pelvic Disease in Unselected Sentinel-
Node Positive Melanoma Patients Treated with Routine Complete Inguinopelvic Lymphadenectomy
C.K. Chu,* K.A. Delman, A. Hestley, G.W. Carlson,
D.E. Murray. Division of Surgical Oncology, Department of Surgery, Emory University School of Medicine, Atlanta, GA.
P250 Identification of Melanoma Sentinel Nodes with Lymphoseek™: Phase III Clinical Trial Results at Moffitt Cancer Center
V.K. Sondak,* S. Marzban, C.J. Rich, J.L. Messina,
J.S. Zager. Dept of Cutaneous Oncology, Moffitt Cancer Center, and University of South Florida College of Medicine, Tampa, FL.
P251 Effect of Body Mass Index on Overall Survival in Patients with Stage III Melanoma
C.M. Shaw,1* F. Zhu,2 S. Lessin,3 E. Sigurdson.1 1. Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA;
2. Biostatistics, Fox Chase Cancer Center, Philadelphia, PA; 3. Dermatology, Fox Chase Cancer Center, Philadelphia, PA.
P252 Prognostic Factors in Patients with Locally Advanced Cutaneous Squamous Cell Carcinoma of Trunk and Extremities
Vazquez,1* N.M. Perpetuo,1 T. Sachetto,1
Scapulatempo,1 A.T. Oliveira,1 J.G. Segalla,2
A.L. Carvalho.1 1. Surgery, Hospital de Cancer de Barretos, BarretosSP, São Paulo, Brazil; 2. Hospital Amaral Carvalho, Jaú, São Paulo, Brazil.
P253 Risk of Lymphedema Following Sentinel Node Biopsy (SNB) for Lower Extremity Melanoma
R.A. Graham,* P. Magoon, Y. Lee, J. Rothschild. Tufts Medical Center, Boston, MA.
P254 Thoracic Metastasectomy for Procurement of Tumor Infiltrating Lymphocytes in Melanoma Patients
Klapper,* J.L. Davis, F.O. Smith, R.T. Ripley,
Mathur, C.D. Kemp, D.M. Nguyen, K.F. Kwong,
Mercedes, D.E. White, M.E. Dudley, J.R. Wunderlich,
S.A. Rosenberg, D.S. Schrump. Surgery Branch, National Cancer Institute, NIH, Bethesda, MD.
P255 Standards for Lymph Node Ratio in Dissections for Melanoma Patients: Can They Be Achieved?
N. Goel,2* R.L. Askew,1 Y. Xing,1 M.I. Ross,1
J.E. Gershenwald,1 J.E. Lee,1 P.F. Mansfield,1 A. Lucci,1
R.E. Royal,1 J.N. Cormier.1 1. Surgery, UT MD Anderson Cancer Center, Houston, TX; 2. University of Illinois at Chicago, Chicago, IL.
P256 Prognostic Significance of Pelvic Nodal Drainage (PLND) at Sentinel Lymph Node (SLN) Mapping for Patients with Extremity Melanoma
G.C. Karakousis,1* N. PanditTaskar,1 S. Atherton,2
M. Hsu,1 K. Panageas,1 C. Ariyan,1 M. Brady.1 1. Memorial SloanKettering Cancer Center, New York City, NY;
2. University of Queensland, Brisbane, QLD, Australia.
P257 Intraoperative Sentinel Lymph Node Analysis in Melanoma
C. Pierce,* R. Broadwater, K. Westbrook, S. Korourian,
D. Davis, K. Hiatt, J. Lee, S. Klimberg, B. Badgwell.
Surgical Oncology, University of Arkansas for Medical
Sciences, Little Rock, AR.
P258 The Prognostic Value of FDG-PET Measured By Standardized Uptake Value in Patients with Melanoma Stage III; Evaluated in a Prospective Study
E. Bastiaannet,1* O.S. Hoekstra,2 J.R. De Jong,1
A.H. Brouwers,1 A.J. Suurmeijer,1 H.J. Hoekstra.1
1. UMCG, Groningen, Netherlands; 2. VUMC, Amsterdam, Netherlands.
P259 Invasive Melanoma of the Face: Patterns of Local and Regional Disease in 261 Patients
A.J. Chambers,* T. Murynka, J.P. Arlette, J.G. Mckinnon.
University of Calgary, Calgary, AB, Canada.
P260 Elevated S-100B Concentrations and Levels of Fluorodeoxyglucose Uptake Predict Decreased Overall and Disease Free Survival in Stage III Melanoma Patients
S. Kruijff,* E. Bastiaanet, A. Brouwers, H. Hoekstra.
University Medical Centre Groningen, Groningen, The Netherlands.
P261 Increased Serum S-100B Level in Melanoma Patients During Follow-Up and Utility Of FDG PET/CT and Brain MRI
T.S. Aukema,* R.A. Valdés Olmos, T.M. Korse, B.B. Kroon,
M.W. Wouters, W.V. Vogel, J.M. Bonfrer, O.E. Nieweg.
Netherlands Cancer Institute/Antoni van Leeuwenhoek
Hospital, Amsterdam, Netherlands.
P262 Does Increased Experience with Isolated Limb Infusion for Advanced Melanoma Influence Outcome? A Comparison of Two Treatment Periods at a Single Institution
A.M. Huismans,1* H.M. Kroon,1 P.C. Kam,2
J.F. Thompson.1 1. Melanoma Institute Australia, Sydney, NSW, Australia; 2. Department of Anaesthetics, Royal Prince Alfred Hospital, Sydney, NSW, Australia.
P263 Better Understanding of Cutaneous Apocrine Adenocarcinoma Using National Tumor Registry
K. Hollowell,* S. Agle, E. Zervos, T. Fitzgerald. Surgery, Brody School of Medicine, Greenville, NC.
P264 Long-Term Follow-Up After Sentinel Lymph Node Biopsy in Melanoma Patients
M. De Vries, M.J. Speijers,* R.J. Van Ginkel, J.T. Plukker,
A.J. Suurmeijer, A.H. Brouwers, C. Lemstra, H.J. Hoekstra.
University Medical Center Groningen, Groningen,
Netherlands.
P265 Prospective Evaluation of PET/CT as a Surveillance Tool to Define Response to Therapy and Identify New Recurrent Disease in Patients with Locally Advanced Melanoma Undergoing Regional Chemotherapy Treatment with Melphalan
G.M. Beasley,* A. Selim, N.S. McMahon, A. Coleman,
A.P. Abernethy, K. Nelson, S.K. Pruitt, H. Seigler, T. Wong,
M. Onaitis, D.S. Tyler. Duke University, Durham, NC.
P266 Melanoma Cells Have Phosphorylated c-Met Through Autocrine Signaling By HGF, Leading to Downstream Effects on Src and MAPK
A. Shada,* K.R. Molhoek, C.L. Slingluff, Jr. Surgery, University of Virginia, Charlottesville, VA.
P267 Human Acellular Cadaveric Dermis as Definitive Reconstruction after Excision of Skin and Soft Tissue Malignancies
K.K. Turaga,* S.S. Marzbaan, E.L. Cox, C.A. Puleo,
R.J. Gonzalez, J.S. Zager, V.K. Sondak. H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
P268 Sun Protection Outreach Teaching by Students (SPOTS): Skin Cancer Education in the Adolescent Population
M. Boyce,1* S. Lickerman,3 M.K. Ruhlman,1 K. Martin,1
K. Ward,1 S. Pickett,1 M. Jung,2 N. Nejedly,2 W. Zeng,2
S.W. Fosko,1 S. Jensen,1 F.E. Johnson,1 X. SPOTS working group.3 1. Saint Louis University, Saint Louis, MO; 2. Washington University, Saint Louis, MO; 3. Melanoma Hope Network, Saint Louis, MO.
P269 Detection of Nodal Recurrence in Melanoma By Patient or Doctor Has No Influence on Survival
S. Kruijff,* E. Bastiaannet, A. Suurmeijer, H.J. Hoekstra.
University Medical Centre Groningen, Groningen,
Netherlands.
Quality Improvement/Clinical Outcomes
P270 Determinants of Resource Utilization In Pancreatoduodenectomy: A Multicenter Analysis of 1467 Patients
P.K. Gupta,1* K.K. Turaga,2 H. Gupta,1 W.J. Miller,3
B.W. Loggie,1 J.M. Foster.1 1. Creighton University, Omaha, NE; 2. H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; 3. University of Virginia, Charlottesville, VA.
P271 Is Time to Delivery of Treatment a Reliable Measure of Quality of Care for Patients with Colorectal Adenocarcinoma?
C.R. Roland,* R.E. Schwarz, L. Tong, C. Ahn, G.C. Balch,
A.C. Yopp, T.A. Anthony, J.C. Mansour. Surgical Oncology, University of Texas Southwestern, Dallas, TX.
P272 Timely Access and Quality of Care in Colorectal Cancer: A Population-Based Analysis
G. Porter,1* R. Urquhart,2 J. Bu,2 Y. McConnell,1
E. Grunfeld.3 1. Dalhousie University and QEII Health Sciences Centre, Halifax, NS, Canada; 2. Cancer Care Nova Scotia, Halifax, NS, Canada; 3. University of Toronto, Toronto, ON, Canada.
P273 Venous Thromboembolism Prophylaxis with Sequential Compression Devices, Early Ambulation, and Dextran (SEED) is a Safe, Effective and Easily Reversible Surgical Prophylaxis Intervention in Peritoneal Carcinomatosis Management
P.K. Gupta,* J.V. Blas, J.H. Carreau, T.E. Grotz,
B.W. Loggie, J.M. Foster. Surgery, Creighton University Medical Center, Omaha, NE.
P274 Patient Surveillance after Curative-Intent Treatment for Ovarian Cancer
G. Harmandayan,1* K.S. Virgo,2 F. Gao,3 D.G. Mutch,3
F.E. Johnson.4 1. Surgery, Saint Louis University, St. Louis, MO; 2. American Cancer Society, Atlanta, GA;
3. Washington University, Saint Louis, MO; 4. Veterans Affairs Medical Center, Saint Louis, MO.
P275 High Resolution Intra-operative Two Dimensional Specimen Mammography and its Impact on Second Operation for Re-excision of Positive Margins at Final Pathology after Breast Conservation
L. Bathla,1* A. Harris,1 M. Davey,2 P. Sharma,3 E. Silva.4
1. Creighton University Medical Center, Department of Surgery, Omaha, NE; 2. Creighton University Medical Center, Department of Radiology, Omaha, NE;
3. Creighton University Medical Center, Department of Pathology, Omaha, NE; 4. University of Nebraska Medical Center, Department of Surgery, Omaha, NE.
P276 Predictors of Pulmonary and Cardiac Complications Following Pancreatoduodenectomy
P.K. Gupta,1* H. Gupta,1 K.K. Turaga,2 W.J. Miller,3
B.W. Loggie,1 J.M. Foster.1 1. Creighton University, Omaha, NE; 2. H, Lee Moffitt Cancer Center and Research Institute, Tampa, FL; 3. University of Virginia, Charlottesville, VA.
P277 The Effect of Surgeon Volume on Lymphedema Development in Older Breast Cancer Women
T. Yen,* C. Guo, R. Sparapani, P. Laud, A. Nattinger.
Surgery, Medical College of Wisconsin, Milwaukee, WI.
P278 Prospective Identification of Vulnerability in Older Patients Undergoing a Pancreaticoduodenectomy: A Pilot Study
Roggin,* J. Hemmerich, J. Wallace, C. Martens,
Karr, A. Kamm, J.C. Baretto, J.B. Matthews, M.C. Posner, W. Dale. Surgery, University of Chicago, Chicago, IL.
P279 Withdrawn
P280 Outcomes after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Surface Dissemination from Ovarian Neoplasms
N. Parson,* P. Shen, G.B. Russell, S.S. Lentz, E.A. Levine,
J.H. Stewart. General Surgery, Wake Forest University School of Medicine, WinstonSalem, NC.
P281 Evaluation of the Cost-Effectiveness of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (Peritonectomy) at the St. George Hospital Peritoneal Surface Malignancy Program
T.C. Chua,* S. Martin, A. Saxena, W. Liauw, T.D. Yan,
J. Zhao, I. Lok, D.L. Morris. UNSW Department of Surgery, St George Hospital, Sydney, NSW, Australia.
P282 The Effect of Splenectomy or Radiation Therapy on Survival for Patients with Hematologic Malignancies
S. Misra,* N. Solomon, Y. Zhuge, L. Koniaris. Surgical Oncology, University of Miami, Miami, FL.
P283 Is NCDB Data Valid For Estimating Completion Node Dissection Rate After Sentinel Node Biopsy In Melanoma?
K.K. Turaga,* S.S. Marzbaan, E.L. Cox, V.K. Sondak,
J.S. Zager. H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
P284 Use Post-Mastectomy Breast Reconstruction in the Greater Sacramento Area: Disparities on the Rural to Urban Continuum
W.H. Tseng,* R.J. Bold, R.J. Canter, S.L. Chen, V.P. Khatri,
S.R. Martinez. Surgery, UC Davis Cancer Center, Sacramento, CA.
P285 Thromboprophylaxis Is Not Necessary in Patients Who Undergo Major Oncological Abdominal Surgery With Pre-Operative Epidural Analgesia
F.F. Amersi,* T.K. Sibert, K. Sibert MD, E. Hemaya MD,
A.W. Silberman MD, PhD. Sugical Oncology, CedarSinai Medical Center, Los Angeles, CA.
P286 Patient Satisfaction with Timeliness of Care in Surgically-Treated Gastric Cancer
L. Donahoe,* K. Druhan, K. Inglis, G. Porter. Dalhousie University, Halifax, NS, Canada.
P287 Measuring the Quality of Sentinel Lymph Node Biopsy (SLNB) for Breast Cancer in Ontario: A Population Based Evaluation
M. Quan,1* B.J. Wells,2 R. Saskin,3 N. Fraser,2 F.C. Wright,2
D.R. Urbach,3 D.R. McCready.4 1. Department of Surgery, Foothills Medical Centre, Calgary, AB, Canada;
2. Sunnybrook Health Sciences Centre, Toronto, ON, Canada; 3. Institute for Clinical and Evaluative Sciences, Toronto, ON, Canada; 4. Princess Margaret Hospital, Toronto, ON, Canada.
P288 Extra Pulmonary Small Cell Cancers: A Population Based Study Comparing Epidemiology and Survival Rates with Pulmonary Small Cell Cancers
S. Misra,* N. Solomon, Y. Zhuge, L. Koniaris. Surgical Oncology, University of Miami, Miami, FL.
P289 An Acuity Adaptable Patient Care Unit Does Not Change Surgical Outcomes in Patients Undergoing Esophagectomy
A. Kothari,1* M. Hennon,2 T. Bretl,2 A. MunozdelRio,3
T. Weigel.2 1. Department of Surgery, Division of Cardiothoracic Surgery, University of Wisconsin, Madison, WI; 2. University of Wisconsin Department of Surgery, Division of Cardiothoracic Surgery, Madison, WI;
3. University of Wisconsin Department of Surgery, Division of Biostatistics, Madison, WI.
P290 Peritoneal Carcinomatosis in the Geriatric Patient: Outcomes with Cytoreductive Surgery and HIPEC
H.A. Thieme,* V. Gushchin, A. Sardi, N. Athas. Dept of Surgical Oncology, Mercy Medical Center, Baltimore, MD.
P291 Esophagectomy in the State of Florida: Is Regionalization of Care Warranted?
K. BenDavid, D. Ang, S.R. Grobmyer, T. Kim,
S. Hochwald.* Surgery, University of Florida College of Medicine, Gainesville, FL.
P292 Analysis of Receptor Tyrosine Kinase Activation in Peritoneal Mesothelioma Treated by Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy
M. Deraco,* F. Perrone, A.D. Cabras, D. Baratti,
N. Zaffaroni, G. Jocollè, S. Kusamura, S. Pilotti.
Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
P293 Complications Following Elective Hepatic Resection for Malignancy: Are They Associated with Institutional Volume?
G.D. Young,1* C.J. Gannon,1 V. Dombrovskiy,2
D.R. Carpizo,1 T.R. Vogel.2 1. Cancer Institute of New Jersey, New Brunswick, NJ; 2. Surgical Outcomes Research Group, Robert Wood Johnson Medical School, New Brunswick, NJ.
P294 Schizophrenic Patients with Breast Cancer: Poor Compliance with Adjuvant Chemotherapy
M. Hwang,1* M. Farasatpour,1 C. Williams,1
J.A. Margenthaler,2 K.S. Virgo,3 F.E. Johnson.1 1. Surgery, Saint Louis University, Saint Louis, MO; 2. Washington University, Saint Louis, MO; 3. American Cancer Society, Atlanta, GA.
P295 Cytoreductive Surgery and Intraperitoneal Chemotherapy Improve Survival in Patients with Peritoneal Carcinomatosis from Colorectal Cancer
J. Ojo,* S. McKenzie, R. Morgan, B. Paz, L. Leong,
J. Ellenhorn, J. GarciaAguilar, L. Lai. Surgery, City of Hope Hospital, Duarte, CA.
* designated presenter
P296 Malignancies After Renal Transplantation
E. Bastiaannet,2* J.J. Homanvan der Heide,1 R.J. Ploeg,1
H.J. Hoekstra.1 1. UMCG, Groningen, Netherlands; 2. CCCNE, Groningen, Netherlands.
P297 Quality of Care for Colorectal Cancer Patients in Japan – An Analysis of the Japanese Colorectal Cancer Registry
M. Ishiguro,1* T. Higashi,2 K. Sugihara,1 T. Sobue.3
1. Department of Surgical Oncology, Tokyo Medical and Dental University, Tokyo, Tokyo, Japan; 2. The University of Tokyo, Graduate School of Medicine, Department of Public Health/Health Policy, Tokyo, Japan; 3. Center for Cancer Control and Information Services, National Cancer Center, Tokyo, Japan.
Sarcome
P298 Perioperative Morbidity and Mortality for Extremity and Truncal Soft Tissue Sarcomas: Insight from the NSQIP Database
M. Raoof,1* W.H. Tseng,2 R.M. Tamurian,2 R.J. Canter.2
1. University of Arizona, Tucson, AZ; 2. Surgery/Surgical Oncology, UC Davis Medical Center, Sacramento, CA.
P299 Alveolar Soft Part Sarcoma: Clinical Features, Treatment and Outcome in a Series of 33 Cases
E. Pennacchioli,* M. Fiore, P. Collini, S. Stacchiotti,
P. Dileo, A. Gronchi. Surgery, National Cancer Institute of Milan, Milan, Italy.
* designated presenter
P300 Desmoid Tumors: Differences in Behavior Based on Site of Disease
A.J. Russ,* J. Yang, C.P. Heise, C.S. Cho, S.M. Weber.
Surgery, University of Wisconsin Hospitals and Clinics,
Madison, WI.
P301 Activation of Peptidergic Neurons by Two Sarcoma Cell Lines
M.A. Lautner,* T.E. Stewart, J.C. Fehrenbacher,
P.E. Scotland, C.B. Gonzales, A.M. Patwardhan,
K.M. Hargreaves. Surgery, UTHSCSA, San Antonio, TX.
P302 Peritoneal Sarcomatosis: Is There a Subset of Patients Who May Benefit of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy?
D. Baratti,* E. Pennacchioli, A. Gronchi, P.G. Casali,
M.R. Balestra, S. Kusamura, C. Colombo, M. Fiore,
M. Deraco. Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy.
P303 Sphincter Preservation for Perirectal Gastrointestinal Stromal Tumors -A “Radical” Departure from Surgical Management in the Past
J. Nitzkorski,1* M. Von Mehren,2 J.C. Watson.1 1. Surgical Oncology, Fox Chase Cancer Center, Philadelphia, PA;
2. Fox Chase Cancer Center Medical Oncology, Philadelphia, PA.
P304 Impact of Local Recurrence on Extremity and Pelvic Soft Tissue Sarcoma Survival
P.F. Hwang,1* C.B. Hampton,1 B.K. Potter,2
R.G. Shoemaker,1 J.C. Graybill,1 J.A. Forsberg,1
R.A. Schaefer,2 G.E. Peoples,3 A. Stojadinovic.2 1. Walter Reed Army Medical Center, Washington, DC; 2. Walter Reed Army Medical Center, Uniformed Services University, United States Military Cancer Institute, Washington, DC;
3. Brooke Army Medical Center, Uniformed Services University, United States Military Cancer Institute, Fort Sam Houston, TX.
Thoracic
P305 Histology, Not Lymph Node Involvement Predicts Long-Term Survival in Bronchopulmonary Carcinoids
Johnson,1* S. Trocha,1 M. McLawhorn,4 M. Worley,3
Wheeler,4 L. Thompson,2 N. Schisler,2 D. Schammel,1 C. Schammel,2 J. Stephenson,1 W. Bolton.1 1. Greenville Hospital System, Greenville, SC; 2. Furman University, Greenville, SC; 3. Wofford College, Spartanburg, SC; 4. Medical University of South Carolina, Charleston, SC.
P306 Minimally Invasive Esophagectomy (MIE) is Safe and Effective Following Neoadjuvant Chemoradiation (NACR) Therapy
K. BenDavid, N.A. Kissane, G. Rossidis, S.R. Grobmyer,
J.C. Cendan, G.A. Sarosi, S. Hochwald.* Surgery, University of Florida College of Medicine, Gainesville, FL.
P307 The Roles of Neoadjuvant Radiotherapy and Lymphadenectomy in the Treatment of Esophageal Adenocarcinoma
N.L. Solomon,* Y. Zhuge, M. Cheung, D. Franceschi,
L. Koniaris. Surgical Oncology, University of Miami, Miami, FL.
P308 An Abbreviated Thoracic Onco Geriatric Assessment (TOGA) and Its Components Predict Outcomes of Esophagectomies
T. Weigel,2* A. Kothari,1 T. Bretl,2 K. Block,2
N.K. LoConte.3 1. Department of Surgery, Division of Cardiothoracic Surgery, University of Wisconsin, Madison, WI; 2. University of Wisconsin Department of Surgery, Division of Cardiothoracic Surgery, Madison, WI;
3. University of Wisconsin Department of Medicine, Division of Hematology/Oncology, Madison, WI.
* designated presenter
P309 Is FDG PET/CT Useful for the Early Prediction of Histopathologic Response to Neoadjuvant Erlotinib in Patients with NSCLC?
T.S. Aukema,1* I. Kappers,1 R.A. Valdés Olmos,1
H.E. Codrington,2 H. Van Tinteren,1 R. Van Pel,1
H.M. Klomp.1 1. Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; 2. Haga Hospital, The Hague, Netherlands.
Disclosure: Grant/Research Support: Roche Netherlands
P310 Gender Disparities and Outcomes in the Surgical Management of Lung Cancer. Analysis of the NIS: 2005-2007
H. Dao,* P. Lee, J. Lee, F. Cotopassi, M.J. Lopez. St. Elizabeth's Medical Center, Boston, MA.
P311 The Benefit of Surgical Resection in the Multimodality Management of Esophageal Cancer
S. McKenzie,1* A. Artinyan,2 B. Mailey,1 M. Metchikian,1
K. Kernstine,1 J. Kim.1 1. City of Hope National Medical Center, Duarte, CA; 2. Baylor University Medical Center, Houston, TX.
P312 Significant Impact of Phase Transitions and Cell Ratio Factors For 5-Year Survival of Cardioesophageal Cancer Patients after Surgery
O. Kshivets.* Thoracic Surgery, Klaipeda University Hospital, Siauliai, Lithuania.
P313 SCCRO-3 (DCUN1D3) is Underexpressed in Human Lung Cancer and is a Novel Tumor Suppressor Gene
C.T. Stock,1* C. Bommelje,2 G. Huang,2 R. Ryan,2
S. Bains,2 Y. Ramanathan,2 B. Singh.2 1. Surgery, New York Presbyterian Hospital Weill Cornell, New York, NY; 2. Memorial Sloan Kettering Cancer Center, New York, NY.
P314 Radiofrequency Ablation as an Adjunct to Systemic Chemotherapy for Colorectal Pulmonary Metastases
T.C. Chua,* K. Thornbury, A. Saxena, W. Liauw, D. Glenn,
J. Zhao, D.L. Morris. UNSW Department of Surgery, St George Hospital, Sydney, NSW, Australia.
Urology
P315 Increased Colorectal Cancer Risk after Radiation Therapy for Prostate Cancer
A.M. Leung,* H.N. Vu. Medical College of Virginia Virginia Commonwealth University, Richmond, VA.
Objectives: Upon completion of this session, participants should be able to: (P315) discuss the potential increased risk of a secondary primary colorectal cancer after radiotherapy for prostate cancer.
* designated presenter
Go To: Wednesday's Sessions | Thursday's Sessions | Friday's Sessions | Saturday's Sessions | Sunday's Sessions | All Posters